Introduction {#s1}
============

Despite recent advances in cancer therapeutics, there remains a dearth of effective treatments. Therefore, expanding the number of candidate therapeutic targets in cancer is crucial. Cancer 'driver genes', which undergo positive selection due to their effects on oncogenes or tumor suppressor genes, represent cancer vulnerabilities that are broadly considered as potential therapeutic targets ([@bib11]; [@bib18]; [@bib57]). However, alterations of non-driver genes, which do not contribute to oncogenesis but are nevertheless observed, represent an emerging class of candidate therapeutic target that have yet to be fully explored.

During the course of tumorigenesis, most cancers undergo somatic copy number alterations (SCNAs) affecting large fractions of the genome (See Appendix Note) ([@bib6]). Yet most genes affected by SCNAs likely do not contribute to oncogenesis and are therefore overwhelmingly genetically altered non-driver genes. Recently, our laboratory and others have described potential new therapeutic targets that occur as a result of SCNAs affecting non-driver genes. For example, partial copy-loss of the proteasome subunit *PSMC2*, or RNA polymerase subunit *POLR2A* sensitized cancer cells to further suppression of those genes ([@bib36]; [@bib44]). This 'CYCLOPS' (Copy-number alterations Yielding Cancer Liabilities Owing to Partial losS) phenotype suggests that many additional cancer vulnerabilities exist as a result of SCNAs that affect non-driver genes, although some CYCLOPS genes may function as driver genes when affected by other genetic alterations besides partial copy-loss. The frequency of these CYCLOPS gene dependencies and their general features are largely unknown.

These CYCLOPS genes tend also to be cell essential genes. While essential genes would be expected to be poor therapeutic targets because of their requirement for survival in all tissues, therapeutic windows can still exist ([@bib43]). Identifying which essential genes may be considered CYCLOPS genes, and the mechanisms underlying how normal cells tolerate partial loss of function, is necessary for developing approaches to target those therapeutic windows.

The spliceosome is one such essential protein complex that can be therapeutically targeted in cancer. Previous work suggested spliceosome components were enriched as candidate CYCLOPS genes ([@bib44]). However, spliceosome CYCLOPS dependencies have yet to be validated and the molecular mechanisms for how spliceosome CYCLOPS dependencies arise remain unclear. Compounds have been discovered that inhibit pre-mRNA splicing, with reports of broad anti-neoplastic effects ([@bib59]). Furthermore, cancers can harbor recurrent mutations in splicing factors ([@bib17]), including gain-of-function mutations in *SF3B1* ([@bib19]; [@bib24]; [@bib27]; [@bib47]; [@bib58]; [@bib61]) that can sensitize cells to spliceosome modulatory drugs ([@bib46]). In addition to SF3B1 mutations, other genomic alterations in SF3B1, including copy number alterations, may also unveil novel cancer vulnerabilities. The extent to which SF3B1 and other splicing factors can be leveraged as therapeutic targets in cancer is not fully understood.

We therefore sought to systematically evaluate the prevalence of CYCLOPS dependencies relative to other SCNA-associated gene dependencies in cancer. Here, we report that CYCLOPS dependencies are the most enriched class of copy-number associated gene dependency, even more frequent than amplification of oncogene-addicted driver gene. We find that CYCLOPS genes tend to be a subset of essential genes for which there is little feedback regulation in their expression when altered by SCNAs. We also find that more CYCLOPS gene dependencies are associated with spliceosome components than with any other gene family.

We find that wild-type SF3B1 is a non-driver CYCLOPS gene dependency and describe the mechanism behind this dependency. Furthermore, the molecular mechanism of the SF3B1 CYCLOPS dependency is distinct from SF3B1 dependencies targeted by current spliceosome inhibitors. We also identify the deubiquitinase inhibitor (DUBi's), b-AP15, can reduce SF3B1 protein levels and target the SF3B1 CYCLOPS dependency. Moreover, DUBi's may represent a general therapeutic approach to target CYCLOPS gene vulnerabilities. The identification of *SF3B1* as a CYCLOPS gene highlights a previously unrecognized cancer vulnerability and implicates non-driver alterations of wild-type SF3B1 as a potential therapeutic target present in 11% of all cancers.

Results {#s2}
=======

Most copy-number associated cancer dependencies result from genomic loss {#s2-1}
------------------------------------------------------------------------

We interrogated copy-number associated vulnerabilities genome-wide across 179 cell lines by integrating gene dependency data from Project Achilles ([@bib13]) with copy-number calls for 23,124 genes ([@bib3]) ([Figure 1A](#fig1){ref-type="fig"}). The gene dependency data represented the effects on proliferation of 55,416 shRNAs targeting 11,589 unique genes, processed by the ATARiS method to estimate effects of 'on-target' shRNAs ([@bib51]), which yielded 8724 unique gene-level dependency scores. For every pair of genes in the general analysis, we calculated Pearson correlations between the copy-number of the first gene and the dependency score of the second; yielding 201,733,776 parings in total ([Figure 1A](#fig1){ref-type="fig"}). We calculated p-values for each correlation and q-values to correct for multiple hypotheses (see Materials and methods). In many cases, a single gene dependency profile correlated with copy-number profiles of multiple genes from a single genomic region. We considered these to represent a single 'independently significant' interaction with the overall copy-number of that region.10.7554/eLife.23268.002Figure 1.Analysis of copy-number-associated gene dependencies.(**A**) Schematic describing the general analysis of copy-number-associated gene dependencies. (**B**) Significance of enrichment for positive copy-number:gene dependency associations across *trans* and *cis* association classes, relative to the expected share assuming all possible interactions exhibited equal likelihood of positive association. (**C**) Percent of genome lost across 31 TCGA cancer types. Cancer types are indicated by TCGA abbreviations (see <https://tcga-data.nci.nih.gov/datareports/codeTablesReport.htm>, 'Disease Study' table). (**D**) Schematic describing the approach to identify CYCLOPS genes. (**E**) Relative strength (delta ATARiS score) of CYCLOPS genes (orange circles; left axis) and frequency of hemizygous deletion (solid black line; right axis) against genomic position (x-axis). (**F**) The number of CYCLOPS genes lost per tumor for various tumor types as in (**C**). Horizontal black lines represent medians per tumor type. (**G**) Distribution of variances in gene expression for different gene classes, normalized to expression level (see Materials and methods), in normal tissues. Whiskers represent min/max values and boxes represent upper and lower quartile ranges. Width of plots represents relative sample density.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.002](10.7554/eLife.23268.002)10.7554/eLife.23268.003Figure 1---figure supplement 1.Analysis of copy-number-associated gene dependencies.(**A**) Percent of genome affected by copy-loss across 10,570 cancers. (**B**) The fraction of the genome undergoing copy-loss as a function of the size of the copy-loss event. Fractions of a chromosome arm \>1 reflect events affecting both chromosome arms; '2' represents the whole chromosome. (**C**) Schematic for the loss of a tumor suppressor gene with focal inactivation of one allele (red line) and corresponding chromosome arm-level loss of the remaining allele. (**D**) Average percent decrease in gene expression upon copy-loss (y-axis) for non-CYCLOPS genes vs CYCLOPS genes across 16,867 genes and 1011 cancer cell lines. (**E**) Pearson correlation coefficients (y-axis) for associations between copy-number and gene expression across 16,867 genes and 1011 cancer cell lines. Red dots represent individual genes, black bars represent mean Pearson correlation coefficients for each group. For all panels: \*\*\*p\<0.0001, error bars represent ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.003](10.7554/eLife.23268.003)

In the general analysis, we identified 50 independently significant copy-number:gene-dependency interactions (q \< 0.25; [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}). Approximately two-thirds (33/50) of these interactions involved genes on separate chromosomes (*trans* interactions). Among the 33 *trans* interactions, 21 reflected sensitization to suppression of a gene resulting from copy-loss of a different genomic region; the other 12 resulted from copy-gains. The *trans* gene dependencies identified were enriched for members of macromolecular complexes (q = 2.5×10^−4^). In three cases, copy-loss of a gene (*PPP2CB*, *FUBP2*, or *MAGOH*) was associated with increased sensitivity to suppression of its paralog (*PPP2CA*, *FUBP1*, and *MAGOHB*, respectively). In contrast, all but one interaction (16/17) between genes on the same chromosome (*cis* interactions) involved increases in sensitivity to suppression of a gene that had undergone copy-loss (CYCLOPS genes) ([@bib44]). As a result, 74% of all 50 significant copy-number:gene-dependency interactions were associated with copy-loss rather than gain (p=1.5×10^−4^).

Most cancers exhibit losses of candidate CYCLOPS genes {#s2-2}
------------------------------------------------------

Although CYCLOPS interactions represent 0.004% (8,724/201,733,776) of all potential interactions in the general analysis, they constituted one-third of all significant interactions, making them the most enriched class of copy-number synthetic lethal interactions we identified ([Figure 1B](#fig1){ref-type="fig"}). Their prevalence is partly the result of frequent genomic loss in cancer genomes. Specifically, across 10,570 cancers spanning 31 cancer types profiled by The Cancer Genome Atlas (TCGA), 16% of the genome undergoes loss in the average cancer ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), mainly due to losses encompassing chromosome arms or entire chromosome ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Indeed, loss of a tumor suppressor often involves such arm-level losses ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). The fraction of the genome lost per tumor ranged from an average of 1.3% in thyroid cancer to 34.4% in ovarian cancer ([Figure 1C](#fig1){ref-type="fig"}).

To enhance the identification of CYCLOPS genes, we performed a genome-wide analysis focused on just CYCLOPS dependencies ([Figure 1D](#fig1){ref-type="fig"}; Materials and methods). The CYCLOPS analysis had greater power than the general analysis described above because it focused on fewer hypotheses. From the CYCLOPS analysis, we identified 124 candidate CYCLOPS genes ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}), including 87% of the candidate CYCLOPS genes identified in the general analysis ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}). Candidate CYCLOPS genes were distributed across all autosomes ([Figure 1E](#fig1){ref-type="fig"}) and were biased towards areas of frequent copy-loss (p\<10^−15^). The bias toward more frequent copy-loss of candidate CYCLOPS genes may reflect greater statistical power in frequently deleted regions. We also examined the reproducibility of the CYCLOPS analysis using a separate shRNA viability screen across 77 cell lines with a separate analytical approach ([@bib38]) and found 49% (49/103) of the CYCLOPS genes analyzed by both datasets validated in the Marcotte dataset (p\<2×10^−4^, binomial proportion test).

Partial copy-loss of candidate CYCLOPS genes is frequent in cancer genomes. Among the 10,570 TCGA cancers with copy-number data, 71.6% harbored loss of at least one candidate CYCLOPS gene ([Figure 1F](#fig1){ref-type="fig"}). The average number of candidate CYCLOPS genes lost per tumor ranged from one in thyroid cancer to 47 in ovarian cancer.

Candidate CYCLOPS genes tend to be uniformly expressed members of essential complexes {#s2-3}
-------------------------------------------------------------------------------------

Of the 124 candidate CYCLOPS genes, 20 were members of the spliceosome and 11 were members of the proteasome, making these the only significantly enriched KEGG pathways among candidate CYCLOPS genes ([Supplementary file 1D](#SD1-data){ref-type="supplementary-material"}). Candidate CYCLOPS genes are also enriched for essential genes. Genome-wide CRISPR viability data in human cancer cell lines identified 1580 core-essential genes ([@bib25]), including 58% (72/124) of candidate CYCLOPS genes (p\<2×10^−4^, binomial proportion test).

Expression of candidate CYCLOPS genes is markedly uniform across normal tissues. Across RNA-sequencing data from 2342 samples comprising 42 tissue types ([@bib40]), expression of candidate CYCLOPS genes varied significantly less than that of the average gene (p=1.8×10^−15^) and trended towards greater uniformity than non-CYCLOPS essential genes (p=0.07; [Figure 1G](#fig1){ref-type="fig"}).

However, expression of candidate CYCLOPS genes is highly responsive to genomic loss in cancer. We integrated expression profiles for 16,867 genes with copy-number profiles across 1011 cell lines in the Cancer Cell Line Encyclopedia (CCLE) ([@bib3]) to determine the influence of copy-number on gene expression. Upon copy-loss, CYCLOPS gene expression decreased by 28% on average, relative to an 18% decrease among non-CYCLOPS genes (p\<10^−4^, [Figure 1---figure supplement 1D--E](#fig1s1){ref-type="fig"}). These data suggest that cancers with copy-loss of CYCLOPS genes are likely to express them at lower levels than normal tissues.

*SF3B1* is a CYCLOPS gene {#s2-4}
-------------------------

*SF3B1* was among the most significant candidate genes in our CYCLOPS analysis ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}), although it was not detected in our general analysis ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}). The SF3B1 protein is one of seven subunits (SF3B1--5, SF3B14 and PHF5A) of the SF3b complex, which is a constituent of the essential U2 snRNP splicing factor ([@bib55]). Cells with *SF3B1* copy-loss exhibited significantly reduced viability upon partial *SF3B1* suppression relative to cells without *SF3B1* copy-loss (mean dependency scores of −1.14 and 0.01 respectively, p\<10^−5^), which suggests that partial suppression of SF3B1 can be tolerated in certain contexts even though it is an essential gene.

*SF3B1* is partially lost in 11% of the 10,570 cancers from the TCGA PanCan dataset (see Materials and methods for definitions of copy number states). Across all cancers *SF3B1* copy-loss was 5.4 times more common than *SF3B1* mutations, which occur in \~2% of all cancers ([Supplementary file 1C](#SD1-data){ref-type="supplementary-material"}), and mutations and copy-loss were mutually exclusive (p=0.007). Losses were more frequent in breast (20%), urothelial bladder (32%) and chromophobe kidney cancers (71%). Genomic deletions of *SF3B1* typically affect most of the chromosome arm (81% of losses) and are never homozygous (0/10,570 cancers), consistent with characterization of *SF3B1* as an essential gene ([@bib1]; [@bib28]). In contrast, 85% of genes are homozygously deleted at least once among the same 10,570 cancers. Similarly, analysis of copy number alterations from 1042 cancer cell lines in the CCLE indicated 24% of cell lines harbor partial *SF3B1* deletion, including 16/61 (26%) of breast cancer cell lines, but never homozygous loss (0/1042 cell lines).

We established the vulnerability of *SF3B1^loss^* cells to *SF3B1* suppression in both breast and hematopoietic lineages. We tested the proliferation of six breast lines after partial *SF3B1* suppression, including three lines with *SF3B1* copy-loss (*SF3B1^loss^*) and three without either loss or gain of the gene (*SF3B1^neutral^*). Upon partial *SF3B1* suppression, *SF3B1^loss^* cells exhibited significant growth defects but *SF3B1^neutral^* cells or *SF3B1^gain^*cells did not ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Growth defects observed in *SF3B1^loss^* cells included BT549, a near triploid cell line with two copies of *SF3B1*. Partial *SF3B1* suppression also decreased the growth of ESS1, an endometrial cell line harboring an SF3B1^K666N^ mutation ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). However, complete *SF3B1* suppression resulted in growth defects even in *SF3B1^neutral^* cells ([Figure 2---figure supplement 1B--C](#fig2s1){ref-type="fig"}), consistent with previous work establishing *SF3B1* as an essential gene.10.7554/eLife.23268.004Figure 2.Characterization of SF3B1 as a CYCLOPS gene.(**A**) Growth of breast cancer cell lines expressing shLacZ (black) or shSF3B1 (red and orange), measured as changes in CellTiterGlo luminescence relative to one day post-infection. (**B**) Quantitative RT-PCR of *SF3B1* expression from the indicated cell lines expressing shLacZ or shSF3B1 shRNAs normalized to the diploid *SF3B1^neutral^* cell line Cal51. (**C**) Ratio of cells expressing shSF3B1-GFP relative to uninfected controls, normalized to the ratio of cells expressing shLacZ-GFP relative to uninfected controls. Data represent averages from *SF3B1^neutral^* (n = 7) and *SF3B1^loss^* (n = 6) cell lines, using shSF3B1 \#4 in [Figure 2---figure supplement 2E](#fig2s2){ref-type="fig"}. (**D**) Viability of cells expressing TR-shSF3B1\#3 and TRshSF3B1\#5, relative to viability three days post doxycycline administration. (**E**) Viability of cells expressing shLacZ or the average of shSF3B1\#3 and shSF3B1\#4, measured asthe fraction of propidium iodide negative cells, relative to the viability of these cells four days post infection. (**F**) Cell cycle distribution four days after *SF3B1* suppression averaged from TR shSF3B1\#3 and \#5. (**G**) Fraction of apoptotic cells five days after *SF3B1* suppression averaged from TR shSF3B1\#3 and \#5, as determined by AnnexinV/PI flow cytometry. (**H**) Change in ratio of cells expressing SF3B1-GFP relative to uninfected cells. (**I**) Ratio of cells expressing SF3B1-GFP to uninfected cells, in the context of endogenous SF3B1 suppression with TR-shSF3B1 \#5. (**J**) Growth of LacZ and SF3B1 expressing *SF3B1^loss^* cells upon *SF3B1* suppression (TR-shSF3B1\#5), measured as changes in CellTiter-Glo luminescence. For all panels, \*p\<0.05 \*\*p\<0.01 \*\*\*p\<0.001, and error bars represent ± SD from at least three (panels **A**--**G**) or two (**H--J**) replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.004](10.7554/eLife.23268.004)10.7554/eLife.23268.005Figure 2---figure supplement 1.Characterization of SF3B1 as a CYCLOPS gene.(**A**) Growth of *SF3B1^gain^*, SF3B1^control-Cal51-2^ and SF3B1^Loss-Cal51-2^, and SF3B1^K666N^ mutant cells (measured as change in light units; [Figure 2A](#fig2){ref-type="fig"}) after infection with shRNAs targeting LacZ or SF3B1. (**B**) Quantitative RT-PCR of *SF3B1* expression without (black) or with (red) doxycycline-induced shSF3B1 expression using TR-shSF3B1 \#5 demonstrating greater than 85% knockdown. (**C**) Growth of non-transformed *SF3B1^neutral^* cell lines without (black) or with (red) doxycycline-induced shSF3B1 expression using TR-shSF3B1 \#5. Growth curves are measured as changes in CellTiterGlo luminescence relative to day 0 of doxycycline treatment. (**D**) SF3B1 immunoblot from *SF3B1^neutral^* and *SF3B1^loss^* cells expressing shLacZ (**c**) or shSF3B1\#3 (sh3) hairpins performed in parallel to growth assays in [Figure 2A](#fig2){ref-type="fig"}. (**E**) Ratio of GFP-expressing cells to uninfected controls in *SF3B1^neutral^* and *SF3B1^loss^* breast and hematopoietic cell lines expressing shLacZ-GFP (black) or shSF3B1\#4-GFP (red). (**F**) Heatmap of False Discovery Rate q-values indicating the significance of associations between copy numbers of SF3b complex members (rows) and sensitivity of those cells to suppression of SF3b complex members by shRNA (columns). (**G**) PHF5A immunoblot three days after infection with shLacZ or shPHF5A targeting hairpins from HCC1954 cells profiled in panel [Figure 2---figure supplement 1G](#fig2s1){ref-type="fig"}. (**H**) Growth of breast cancer cell lines expressing shLacZ (black) or shPHF5A (red), measured as changes in CellTiterGlo luminescence relative the day of infection. For all panels, error bars represent ± SD from at least three technical replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.005](10.7554/eLife.23268.005)10.7554/eLife.23268.006Figure 2---figure supplement 2.Further characterization of SF3B1 as a CYCLOPS gene.(**A**) Quantitative RT-PCR of *SF3B1* expression without (black) or with (red) doxycycline-induced shSF3B1 expression relative to the diploid cell line Cal 51. (**B**) Growth of breast cancer cell lines without (black) or with (red) doxycycline-induced shSF3B1 expression, measured as changes in CellTiterGlo luminescence relative to day 0 of doxycycline treatment. (**C**) GFP fluorescence from cells expressing SF3B1-IRES-GFP without (black) or with (red) doxycycline-induced TR-shSF3B1\#5 expression. (**D**) SF3B1 immunoblot from HCC1954 cells expressing LacZ or SF3B1. For all panels, error bars represent ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.006](10.7554/eLife.23268.006)

The *SF3B1* shRNAs used to unveil the CYCLOPS vulnerability targeted separate regions of the gene and resulted in partial *SF3B1* knockdown across all eleven breast cell lines ([Figure 2B](#fig2){ref-type="fig"}). However, *SF3B1^loss^* cells had greater levels of knockdown due to lower *SF3B1* expression at baseline, which was confirmed at the protein level in four of these lines by immunoblot ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}).

We also generated similar results in isogenic *SF3B1^loss^* cells derived from the *SF3B1^neutral^* cell line Cal51. We generated *SF3B1^loss^* cells using two independent CRISPR-Cas9 mediated methods of gene editing (see Materials and methods). The first line contained a frameshift mutation inactivating one *SF3B1* allele (SF3B1^Loss-Cal51-1^). The second line had deletion of one copy of the *SF3B1* locus, generated by co-expressing two sgRNAs: one upstream targeting a heterozygous SNP, and one downstream of *SF3B1* (SF3B1^Loss-Cal51-2^). In both cases CRISPR-mediated *SF3B1* loss resulted in decreased proliferation upon *SF3B1* suppression relative to cells that were generated in parallel but did not produce inactivating alleles (SF3B1^control-Cal51^ cells; [Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}).

We confirmed the vulnerability of the *SF3B1^loss^* cells to *SF3B1* partial suppression using a GFP-competition assay in which we compared the proliferation rate of uninfected cells co-cultured with cells infected with a vector that co-expressed GFP and an shRNA targeting either *LacZ* or *SF3B1*. The expression of *LacZ* or *SF3B1* shRNAs did not result in significant changes in proliferation of *SF3B1^neutral^* cells in seven cell lines, including the non-transformed mammary cell line, MCF10A ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). However, *SF3B1^loss^* cells expressing *SF3B1* shRNAs were not compatible with long-term culture ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}).

The *SF3B1* CYCLOPS vulnerability is not recapitulated by suppression of other SF3b complex subunits, and copy number alterations of other SF3b complex genes do not confer susceptibility to *SF3B1* suppression. We calculated the significance of associations between Achilles RNAi dependency data of six of the seven SF3b complex subunits (we lacked RNAi data for *SF3B2*) and copy numbers of the genes encoding them ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}). We identified associations between copy numbers of several SF3b subunits and sensitivity to suppressing that same subunit, consistent with our prior determination that multiple SF3b complex subunits are candidate CYCLOPS genes ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). However, we observed no associations between susceptibility to suppression of any of the SF3b complex genes and copy numbers of different SF3b subunits. Further, we confirmed one comparison where suppression of *PHF5A,* an SF3b complex gene, did not alter the growth of *SF3B1^loss^* cells ([Figure 2---figure supplement 1G--H](#fig2s1){ref-type="fig"}).

Partial suppression of *SF3B1* leads to both cell cycle arrest and apoptosis in *SF3B1^loss^* but not *SF3B1^neutral^* lines. We generated cultures containing a tetracycline inducible system expressing hairpins targeting *Luciferase* or *SF3B1* (TR-shSF3B1\#3 and an additional hairpin, TR-shSF3B1\#5, [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}), enabling us to discriminate *SF3B1* suppression from infection with shRNA vectors. Consistent with stable *SF3B1* suppression, inducible *SF3B1* suppression retards *SF3B1^loss^* cell growth and does not affect *SF3B1^neutral^* growth ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}) and reduces cell viability in *SF3B1^loss^* cells but not in *SF3B1^neutral^* cells ([Figure 2D and E](#fig2){ref-type="fig"}). *SF3B1^loss^* cells had significantly increased proportions of cells in G2/M phase after *SF3B1* suppression, which did not occur in *SF3B1^neutral^* cells ([Figure 2F](#fig2){ref-type="fig"}). Subsequent to G2/M arrest, *SF3B1^loss^* cells further exhibited a significant induction in apoptosis as determined by increased number of AnnexinV/PI-positive cells that was not observed in *SF3B1^neutral^* cells ([Figure 2G](#fig2){ref-type="fig"}).

Expression of exogenous *SF3B1* rescued the loss of viability in *SF3B1^loss^* cells, confirming the specificity of our shRNAs. We used a lentiviral construct encoding a codon-optimized *SF3B1* ORF, which is resistant to shRNA suppression, fused to an IRES GFP sequence (*SF3B1^WT^*-IRES-GFP). When placed in competition, cells infected or not infected with *SF3B1^WT^*-IRES-GFP maintained constant ratios over 10 days ([Figure 2H](#fig2){ref-type="fig"}), suggesting that short-term expression of *SF3B1* does not alter cellular fitness in either *SF3B1^neutral^* or *SF3B1^loss^* cells. Next, we concomitantly suppressed endogenous *SF3B1* in all cells and expressed *SF3B1^WT^*-IRES-GFP in \~50% of cells. While *SF3B1^neutral^* cells were not affected by partial *SF3B1* suppression, *SF3B1^loss^* cells expressing *shSF3B1* were not compatible with long-term culture. However, *SF3B1^loss^* cells expressing both *shSF3B1* and *SF3B1^WT^*-IRES-GFP persisted ([Figure 2I](#fig2){ref-type="fig"}), indicating that re-expression of *SF3B1* is sufficient to prevent cell death. Furthermore, *SF3B1^loss^* cells expressing both *shSF3B1* and *SF3B1^WT^*-IRES-GFP had a 20-fold increase in GFP fluorescence, suggesting that the exogenous *SF3B1* construct was more highly expressed in *SF3B1^loss^* cells after suppression of endogenous *SF3B1* ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Furthermore, stable exogenous *SF3B1* expression is sufficient to restore the proliferation of *SF3B1^loss^*cells expressing shRNAs targeting *SF3B1* ([Figure 2J](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}).

*SF3B1^neutral^* cells contain excess SF3B1 beyond the requirement for survival {#s2-5}
-------------------------------------------------------------------------------

Analyses of *SF3B1* mRNA indicate that *SF3B1^neutral^* cells tolerate partial *SF3B1* suppression because they express more SF3B1 than the minimum amount needed for survival. In both TCGA breast adenocarcinoma data ([@bib9]) and the Cancer Cell Line Encyclopedia, *SF3B1^neutral^* samples exhibited significantly higher expression of *SF3B1* mRNA relative to *SF3B1^loss^* samples ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}; Mann-Whitney p\<10^−4^, for both datasets), suggesting excess mRNA over requirements for survival. We validated that *SF3B1^neutral^* breast cancer cell lines (n = 7) express approximately twice as much *SF3B1* mRNA as *SF3B1^loss^* cells (n = 5) by quantitative PCR ([Figure 3B](#fig3){ref-type="fig"}; p\<10^−4^). We also found similar *SF3B1* expression changes between the SF3B1^control-Cal51^ and SF3B1^Loss-Cal51^ lines ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).10.7554/eLife.23268.007Figure 3.*SF3B1^neutral^* cells contain excess SF3B1 beyond the requirement for survival.(**A**) *SF3B1* expression from 777 TCGA breast adenocarcinomas segregated by *SF3B1* copy number. Whiskers represent min/max values and boxes represent upper and lower quartile ranges. Width of plots represents relative sample density. (**B**) Quantitative RT-PCR of *SF3B1* expression in breast cancer cell lines. Data points represent individual cell lines, horizontal lines indicate means. (**C**) SF3B1 protein levels in breast cancer cell lines by immunoblot. (**D**) SF3B1 immunoblot from control cells and those with single-copy *SF3B1* inactivation by CRISPR. (**E**) Scatterplot of SF3B1 mRNA and protein expression relative to diploid cell line Cal51 after normalization to actin in a panel of breast cancer cell lines (p=0.0018, R^2^ = 0.772, regression line slope = 0.789). (**F**) SF3B1 immunoblot from SF3B1^neutral^ and SF3B1^loss^ cells 4 days after TR-shSF3B1\#5 induction by doxycycline. (**G**) Differences in proliferation 7 days after SF3B1 suppression (per CellTiter-Glo, see Appendix Methods; red=high, blue=low), against the relative level of SF3B1 expression (assessed by qPCR; y-axis) in SF3B1^neutral^ (left) or SF3B1^loss^ (right) cells expressing either shLacZ (origins of arrows) or shSF3B1 (ends of arrows). Origins with multiple arrows represent cell lines subject to more than one SF3B1 shRNA. Each data point represents the mean from at least two replicate experiments. The dashed line represents the estimated minimum threshold of *SF3B1* expression required for survival. For all panels, \*p\<0.05 \*\*p\<0.01 \*\*\*p\<0.001, and error bars represent ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.007](10.7554/eLife.23268.007)10.7554/eLife.23268.008Figure 3---figure supplement 1.Further characterization of SF3B1 as a CYCLOPS gene.(**A**) *SF3B1* expression from 974 cell lines from the CCLE classified by *SF3B1* copy-number status. Boxes represent the upper and lower quartiles, whiskers represent the 5--95th percentiles. \*p\<0.0001. (**B**) *SF3B1* mRNA expression from control cells and those with CRISPR-induced copy-loss. \*p\<0.05 and \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.008](10.7554/eLife.23268.008)

Reductions in *SF3B1* mRNA expression were recapitulated at the protein level. Among breast cancer lines, we found increased SF3B1 protein expression in *SF3B1^neutral^* compared to *SF3B1^loss^* cells ([Figure 3C](#fig3){ref-type="fig"}) and SF3B1^control-Cal51^ vs. SF3B1^Loss-Cal51^ cells ([Figure 3D](#fig3){ref-type="fig"}). We also a found significant linear correlation between SF3B1 mRNA and protein expression ([Figure 3E](#fig3){ref-type="fig"}, p=0.0018, R^2^ = 0.772).

These observations suggest that *SF3B1^neutral^* cells tolerate partial *SF3B1* suppression because moderate *SF3B1* suppression leaves them with sufficient residual protein for survival. Indeed, we found detectable SF3B1 levels in *SF3B1^neutral^* cells after *SF3B1* suppression, but failed to detect protein in *SF3B1^loss^* cells after *SF3B1* suppression ([Figure 3F](#fig3){ref-type="fig"} and [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}).

A systematic analysis of shRNA-induced mRNA suppression across *SF3B1^neutral^* and *SF3B1^loss^* lines indicated that *SF3B1* mRNA levels can be reduced by \~60% from *SF3B1^neutral^* cell basal levels before proliferation and viability defects are apparent ([Figure 3G](#fig3){ref-type="fig"}). We suppressed *SF3B1* using shRNAs with different potency to generate a range of *SF3B1* suppression in *SF3B1^neutral^* and *SF3B1^loss^* cells, including shRNAs that suppress SF3B1 by \>70% in *SF3B1^neutral^* cells, and determined the impact on cellular growth seven days after shRNA expression. Although similar reductions in *SF3B1* expression were obtained in *SF3B1^neutral^* and *SF3B1^loss^* lines, the elevated basal levels of *SF3B1* expression in *SF3B1^neutral^* lines enabled them to retain sufficient *SF3B1* for proliferation despite shRNA expression, except in cases when SF3B1 suppression exceeded the 60% threshold of viability.

*SF3B1* copy-loss selectively reduces the abundance of the SF3b complex {#s2-6}
-----------------------------------------------------------------------

We next asked whether the reduction of SF3B1 protein expression in *SF3B1^loss^* cells preferentially altered specific SF3B1-containing complexes. SF3B1 is a component of the seven-member SF3b sub-complex of the U2 snRNP. Incorporation of SF3b into the U2 snRNP 12S 'core' forms the 15S U2 snRNP, which combines with SF3a to form the mature 17S U2 snRNP ([Figure 4A](#fig4){ref-type="fig"}) ([@bib33]; [@bib53]). We therefore interrogated expression levels of native SF3B1-containing complexes from whole-cell extracts by glycerol gradient sedimentation and gel filtration chromatography. We were able to resolve protein complexes from 29--650 kDa and 650--2,000 kDa using 10--30% glycerol gradients and Sephacryl S-500 gel filtration chromatography, respectively ([Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}). This enabled resolution of SF3B1-containing complexes ranging from monomers (155 kDa) to the SF3b sub-complex (450 kDa) to the 15S and 17S U2 snRNPs (790 and 987 kDa, respectively) ([@bib53]). We compared these elution profiles between patient-derived and isogenic *SF3B1^loss^* and *SF3B1^neutral^* cells.10.7554/eLife.23268.009Figure 4.*SF3B1* copy-loss selectively reduces the abundance of the SF3b complex.(**A**) Diagram of U2 snRNP assembly. (**B--C**) Glycerol gradient fractionation of native whole-cell lysates probed by western blot in breast cancer cell lines and (**D--E**) isogenic cells generated by CRISPR. (**F**) Quantification of SF3B1 immunoblots from glycerol gradient fractions 3--8, relative to fraction 3 (n = 3 for each group, see Appendix Methods). (**G**) Serial dilution of pooled glycerol gradient fractions probed for SF3B1 by immunoblot. (**H**) (left) SF3B1 Native PAGE immunoblot of pooled glycerol gradient fractions. (right) denaturing silver stain of total protein from the same pooled fractions as loading control. (**I**) Quantitative RT-PCR for U2 snRNA expression in three *SF3B1^neutral^* and three *SF3B1^loss^* breast cancer cell lines. (**J**) Native agarose gel of U2 snRNP complexes visualized with radiolabeled 2' O-methyl oligonucleotides complementary to the U2 snRNA. Nuclear extracts were generated from SF3B1^control-Cal51^ and SF3B1^Loss-Cal51^ cells. HeLa cell nuclear extracts (NE) ± ATP were used as controls. Representative image from triplicate experiments. (**K**) Densitometric quantification of 17S U2 snRNP bands in (**J**) presented as fold change relative to SF3B1^control-Cal51^ cells. Data are from three replicate experiments. (**L**) Model for changes to U2 snRNP assembly associated with *SF3B1* copy-loss. For all panels, \*p\<0.05, and error bars represent ± SD, ns = not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.009](10.7554/eLife.23268.009)10.7554/eLife.23268.010Figure 4---figure supplement 1.SF3B1 copy-loss selectively reduces the abundance of the SF3b complex.(**A**) Sedimentation of mass standards in 10--30% glycerol gradients. (**B**) Elution profiles of mass standards in gel filtration chromatography columns. (**C**) Quantification of SF3B1 immunoblots from serial dilutions of glycerol gradient fractions in [Figure 4G](#fig4){ref-type="fig"}. SF3B1 abundance normalized by actin loading controls and calculated by densitometry using ImageJ (see Appendix Methods). *SF3B1^neutral^* and *SF3B1^loss^* cells (n = 2 each) quantified from western blot images performed in triplicate. Dots represent mean and error bars are ± SD. (**D**) Immunoblot of indicated gel filtration fractions. GAPDH and SNRPB2 represent markers for complexes \<700 kDa and spliceosome precursors respectively. (**E**) Immunoblot after SF3B1 immunoprecipitation from pooled glycerol gradient fractions 4--6. (**F**) Immunoblot after SF3B1 immunoprecipitation from pooled glycerol gradient fractions 24--25. (**G**) Characterization of U2 oligo specificity. Control HeLa nuclear extracts (NE) were incubated with either U2 snRNA targeting oligonucleotides or control oligonucleotides. For all panels, \*p\<0.05, \*\*p\<0.01 and \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.010](10.7554/eLife.23268.010)

We observed significantly lower levels of SF3b in the *SF3B1^loss^* cells. The largest decreases in SF3B1-containing complexes in glycerol gradients were in fractions 4--8, corresponding to \~29--450 kDa ([Figure 4B--F](#fig4){ref-type="fig"}) and fractions 12--14, corresponding to \~450--650 kDa ([Figure 4G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). We saw similar decreases in gel filtration chromatography fractions corresponding to complexes \<650 kDa ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Native western blotting from the pooled glycerol gradient fractions 4--6 indicated the loss of a single SF3B1-containing complex of \~450 kDa ([Figure 4H](#fig4){ref-type="fig"}). SF3B1 immunoprecipitation from fractions 4--6 resulted in the co-precipitation of SF3b components SF3B3 and SF3B4 in *SF3B1^neutral^* cells, but not of U2 snRNP components SNRPB2 and SF3A3 ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}).

Conversely, it appears that U2 snRNP levels are only modestly decreased in *SF3B1^loss^* lines. Levels of SF3B1 in glycerol gradient fraction 25 (corresponding to \>650 kDa) were not significantly decreased in *SF3B1^loss^* relative to *SF3B1^neutral^* lines ([Figure 4G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). SF3B1 immunoprecipitation from fractions 24--25 resulted in co-precipitation of U2 snRNP components SNRPB2 and SF3A3 ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}). U2 snRNA levels are known to track with U2 snRNP levels, and we also did not observe a significant difference in U2 snRNA abundance between *SF3B1^neutral^* and *SF3B1^loss^* lines ([Figure 4I](#fig4){ref-type="fig"} p=0.35, two-tailed t-test). Similarly, visualization of U2 snRNP complexes using radiolabeled oligonucleotides complementary to the U2 snRNA did not demonstrate differences in 17S U2 snRNP abundance in *SF3B1^loss^* cells ([Figure 4J--K](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}, p=0.68).

These observations suggest that copy-loss of *SF3B1* only modestly affects U2 snRNP abundance but substantially decreases levels of U2 snRNP precursor complexes under steady-state conditions ([Figure 4L](#fig4){ref-type="fig"}).

SF3B1 suppression selectively reduces U2 snRNP abundance in *SF3B1^loss^* cells {#s2-7}
-------------------------------------------------------------------------------

Partial suppression of *SF3B1* leads to substantial reductions of U2 snRNP levels in *SF3B1^loss^* but not *SF3B1^neutral^* cells. Although such suppression results in reduced SF3B1 levels in both *SF3B1^loss^* and *SF3B1^neutral^* lines, only the *SF3B1^loss^* lines exhibit concomitant reductions in levels of U2 snRNP components SF3A3 and SNRPB2 ([Figure 5A](#fig5){ref-type="fig"}). Decreases in SF3A3 and SNRPB2 were observed in glycerol gradient fraction 25, corresponding to the U2 snRNP, most dramatically in *SF3B1^loss^* lines, and to a lesser extent in one of the *SF3B1^neutral^* lines (Hs578T; [Figure 5B](#fig5){ref-type="fig"}). Furthermore, after *SF3B1* suppression, we detected both SF3B1 and SNRPB2 in Sephacryl-S500 fractions containing the \>650 kDa protein complexes in *SF3B1^neutral^* cells but not in *SF3B1^loss^* cells ([Figure 5D--E](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Quantitative PCR also indicated significantly reduced U2 snRNA expression after *SF3B1* partial suppression in *SF3B1^loss^* cells but not in *SF3B1^neutral^* cells ([Figure 5F](#fig5){ref-type="fig"}).10.7554/eLife.23268.011Figure 5.Reduced spliceosome precursors and U2 snRNP abundance upon *SF3B1* suppression in *SF3B1^loss^* cells.(**A**) Western immunoblots without and with SF3B1 suppression prior to glycerol gradient fractionation. (**B**) Western immunoblots from glycerol gradient fraction 25 (protein complexes \>650 kDa). (**C**) Western immunoblots from pooled glycerol gradient fractions 4--6 (protein complexes \~150--450 kDa). (**D**) Immunoblot from lysates prior to gel filtration chromatography. (**E**) Immunoblot of gel filtration fractions 18--26 (protein complexes \>650 kDa) from lysates with *SF3B1* suppression. (**F**) Quantitative RT-PCR for U2 snRNA expression without and with *SF3B1* suppression. (**G**) Glycerol gradient fractions from *SF3B1^neutral ^*cells without and with *SF3B1* suppression compared to *SF3B1^loss ^*without suppression. For all panels, TR-shSF3B1\#5 was used. \*p\<0.05 \*\*p\<0.01 \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.011](10.7554/eLife.23268.011)10.7554/eLife.23268.012Figure 5---figure supplement 1.Reduced spliceosome precursors and U2 snRNP abundance upon SF3B1 suppression in SF3B1^loss^ cells.(**A**) Silver stain of gel filtration inputs for [Figure 5E](#fig5){ref-type="fig"}. (**B**) Quantification of SF3B1 immunoblots from glycerol gradient fraction 25 in [Figure 5B](#fig5){ref-type="fig"}, relative to Cal51 (n = 3 for each cell line, see Appendix Methods). (**C**) Quantification of SF3B1 immunoblots from glycerol gradient fractions 4--6 in [Figure 5C](#fig5){ref-type="fig"}, relative to Cal51 (n = 3 for each cell line, see Appendix Methods). (**D**) Quantification of SF3B1 immunoblots of only the minus doxycycline treated lanes from glycerol gradient fraction 25 in [Figure 5B](#fig5){ref-type="fig"}, relative to Cal51. (n = 2 cell lines per group averaged from three technical replicates per cell line). (**E**) SF3B1 immunoblot from cells used in panel F (with TR-shSF3B1\#5). (**F**) Drug sensitivity curves for indicated splicing modulators in cells without and with *SF3B1* suppression (TR-shSF3B1\#5). (**G**) SF3B1 immunoblot from HMC1--8 cells stably expressing shLacZ or shSF3B1 \#3 used in panel **H**. (**H**) Spliceostatin A drug sensitivity curve for *SF3B1^neutral^* HMC1--8 cells stably expressing shLacZ or shSF3B1 \#3 hairpins. (**I**) Pladienolide B drug sensitivity curves in SF3B1^loss-Cal51^ cells and SF3B1^control-Cal51^ or parental Cal51 cells. For all panels, \*p\<0.05 \*\*p\<0.01 \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.012](10.7554/eLife.23268.012)

In contrast, suppression of *SF3B1* in *SF3B1^neutral^* cells appears to substantially decrease levels of SF3b, but not the U2 snRNP. *SF3B1* suppression in *SF3B1^neutral^* cells only modestly reduced SF3B1 in fraction 25 ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) but instead preferentially reduced SF3B1 from fractions 4--6 ([Figure 5C](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Further, no changes in SF3A3 or SNRPB2 expression were observed in total protein from glycerol gradient inputs ([Figure 5A](#fig5){ref-type="fig"}) or U2 snRNA expression ([Figure 5F](#fig5){ref-type="fig"}). Therefore, we determined if *SF3B1* suppression in *SF3B1^neutral^* cells phenocopies the reduced SF3b observed in unperturbed *SF3B1^loss^* cells. Indeed, *SF3B1^neutral^* cells with *SF3B1* suppression reduced SF3b levels in glycerol gradient fractions 3--6 approximately to the levels observed in *SF3B1^loss^* cells ([Figure 5G](#fig5){ref-type="fig"}). Taken together, these data suggest that the elevated levels of the SF3b sub-complex in *SF3B1^neutral^* cells relative to *SF3B1^loss^* cells appear to buffer *SF3B1^neutral^* cells from reductions in viability following partial *SF3B1* suppression.

Consistent with [Figure 4](#fig4){ref-type="fig"}, *SF3B1^loss^* cells without *SF3B1* suppression did not have significantly lower levels of U2 snRNP in fraction 25 than *SF3B1^neutral^* cells (p=0.16, [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}), suggesting *SF3B1* copy-loss only reduces levels of the U2 snRNP following further depletion of *SF3B1*.

The relative preservation of the U2 snRNP and larger complexes in *SF3B1^loss^* cells without *SF3B1* suppression suggests existing SF3b inhibitors might not exploit the specific vulnerability exhibited by *SF3B1^loss^* cells. SF3b inhibitors modulate U2 snRNP function or subsequent steps during splicing catalysis ([@bib12]; [@bib20]; [@bib49]), thereby altering splicing leading to cell death. With similar U2 snRNP levels in *SF3B1^loss^* and *SF3B1^neutral^* cells, the dose at which these effects would be expected to accrue might be similar.

We tested this hypothesis by exposing *SF3B1^neutral^* cell lines with partial *SF3B1* suppression, and controls to treatment with two SF3b-targeting compounds (Spliceostatin A, and Pladienolide B) and with NSC95397, a compound reported to inhibit splicing activity by an SF3b-independent mechanism ([@bib5]). None of these exhibited increased effects on cells with partial *SF3B1* suppression. ([Figure 5---figure supplement 1E--H](#fig5s1){ref-type="fig"}). We also evaluated isogenic Cal51 cells with engineered SF3B1 copy-loss and did not observe enhanced sensitivity of SF3B1^loss-Cal51^ cell lines ([Figure 5---figure supplement 1I](#fig5s1){ref-type="fig"}).

Partial *SF3B1* suppression results in splicing defects in *SF3B1^loss^* cells {#s2-8}
------------------------------------------------------------------------------

*SF3B1* is well-established as a splicing factor ([@bib23]; [@bib65]), and intron retention has been reported upon treatment of cells with SF3B1 inhibitors ([@bib32]) while patients harboring *SF3B1* mutations display alterations in alternative splicing ([@bib16]; [@bib58]). We therefore quantified the extent of splicing disruption upon *SF3B1* suppression in *SF3B1^neutral^* and *SF3B1^loss^* cells by RNA sequencing. RNA was isolated 4 days after doxycycline treatment when *SF3B1^loss^* cells arrest in G2/M phase of the cell cycle ([Figure 2F](#fig2){ref-type="fig"}), but have not initiated apoptosis ([Figure 2G](#fig2){ref-type="fig"}). We suppressed *SF3B1* in *SF3B1^neutral^* cells to similar or lower levels as seen at steady state in *SF3B1^loss^* cells, and suppressed *SF3B1* in *SF3B1^loss^* cells to even lower levels ([Figure 3F](#fig3){ref-type="fig"} and [Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}). We used juncBase ([@bib8]) and a novel statistical framework to analyze 50,600 splice junctions for intron retention in *SF3B1^neutral^* and *SF3B1^loss^* cells upon *SF3B1* suppression from our RNA sequencing data. Briefly, we calculated the ratio of percent spliced in (PSI) and spliced out read counts for each splicing junction, but accounted for the probability that any single splicing junction may not be accurately sampled in each cell line using a beta binomial distribution (see Appendix Methods).

All cells showed evidence of increased intron retention following *SF3B1* partial suppression (p\<10^−5^), but splicing was significantly more affected in *SF3B1^loss^* cells. Upon *SF3B1* suppression, 7353 transcripts in *SF3B1^loss^* cells showed evidence of significantly (q \< 0.1) increased intron retention relative to *SF3B1^neutral^* cells, whereas only 454 transcripts showed evidence of increased intron retention in the reverse direction ([Figure 6A](#fig6){ref-type="fig"}, p\<10^−1110^).10.7554/eLife.23268.013Figure 6.Partial *SF3B1* suppression results in splicing defects in *SF3B1^loss^* cells.(**A**) Statistical significance of intron retention (see Materials and methods) across all exon-intron junctions (dots) in *SF3B1^neutral ^*(red) and *SF3B1^loss^* cells (blue) after *SF3B1* suppression. The horizontal dashed line represents the significance threshold (q \< 0.01) and the vertical dashed line segregates intron-exon junctions more likely to be altered in *SF3B1^neutral ^*(left) or *SF3B1^loss^* cells (right). (**B**) qPCR for a single intron within the indicated gene without and with *shSF3B1* induction by doxycycline (*SF3B1^neutral^* n = 3, *SF3B1^loss^* n = 3, averaged from TR-shSF3B1\#3 and TRshSF3B1\#5. SF3B1^control-Cal51^ and SF3B1^Loss-Cal51 ^n = 2 each, averaged from TR-shSF3B1\#3). (**C**) Statistical significance of alternative 3' splice site selection (see Materials and methods) across 3' splice junctions (dots) in *SF3B1^neutral ^*(red) and *SF3B1^loss^* cells (blue) after *SF3B1* suppression (as in panel **A**). (**D**) Representative RT-PCR from SF3B1^neutral^ and SF3B1^loss^ cells after *SF3B1* knockdown. 'c' represents LacZ control hairpins, 'sh' represents shSF3B1\#4. Arrows represent product sizes for MCL-L and MCL-S. (**E**) Densitometric quantification of the ratio of MCL1-S:MCL1-L, relative to shLacZ-expressing controls (mean ± SD, n = 3 per group averaged from shSF3B1\#3, and \#4). (**F**) Immunofluorescent images of nuclear speckles by anti-SC35 (SRSF2) staining. Scale bar = 5 uM. (**G**) Quantification of number of nuclear speckles and (**H**) speckle area per cell across at least 100 nuclei. For (**F--H**) TRshSF3B1\#5 was used. (**I**) Number of differentially expressed genes upon *SF3B1* suppression (q \< 0.1) and the number of enriched KEGG pathways amongst indicated gene set (q \< 0.05). For all panels, \*p\<0.05 \*\*p\<0.01 \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.013](10.7554/eLife.23268.013)10.7554/eLife.23268.014Figure 6---figure supplement 1.Partial SF3B1 suppression results in splicing defects in SF3B1^loss^ cells.(**A**) Relative level of SF3B1 expression (assessed by quantitative PCR; y-axis) in *SF3B1^neutral^* (left) or *SF3B1^loss^* (right) cells without doxycycline (black dots, origins of arrows) or with doxycycline (red dots, ends of arrows). Origins with one arrow represents TR-shSF3B1\#3, origins with multiple arrows represent cell lines with TR-shSF3B1\#3 and TR-shSF3B1\#5 done in parallel. Each data point represents the mean from at least two replicate experiments. (**B**) Relative level of *SF3B1* expression in SF3B1^control-Cal51-1^ and SF3B1^Loss-Cal51-1^ with TR-shSF3B1\#3 presented as described in (**A**). (**C**) Schematic of primers designed to detect alternative 3' splice sites in *SLC7A5* and *CELSR1* and representative RT-PCR results from *SF3B1* suppression using TR-shSF3B1\#5 in *SF3B1^neutral^* and *SF3B1^loss^* cells (n = 2 per group). (**D**) Statistical significance of 5' splice site junctions across all 5' splice junctions (dots) in *SF3B1^neutral ^*(red) and *SF3B1^loss^* cells (blue) after *SF3B1* suppression. The horizontal dashed line represents the significance threshold (q \< 0.01) and the vertical dashed line segregates 5' splice junctions more likely to be altered in *SF3B1^neutral ^*(left) or *SF3B1^loss^* cells (right). Alternative 5' splice site selection occurs more frequently in *SF3B1^loss^* cells after *SF3B1* suppression (p=9×10^−165^). (**E**) Scatter plots for ratio of RNA sequencing reads that include a cassette exon without *SF3B1* suppression (no doxycycline, x-axis), or with *SF3B1* suppression (plus doxycycline, y-axis). Each dot represents a single cassette exon in *SF3B1^neutral^* cells (Cal51, Hs587T) and *SF3B1^loss^* cells.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.014](10.7554/eLife.23268.014)

We confirmed increased intron retention in *SF3B1^loss^* cells upon *SF3B1* suppression by qPCR amplifying selected introns of genes from the RNA sequencing analysis ([Figure 6A](#fig6){ref-type="fig"}). Introns were significantly retained in all seven genes analyzed (*AARS, CALR, DNAJB1, MKNK2, MYH9, RPS8* and *RPS18*), which included *DNAJB1,* a gene previously known to be improperly spliced in cells treated with SF3B1 inhibitors ([@bib32]), and cell essential genes *AARS*, *RPS8* and *RPS18* ([Figure 6B](#fig6){ref-type="fig"}).

The SF3b complex is known to regulate 3' splice site selection ([@bib16]). We therefore analyzed 30,666 alternative 3' splice sites from the RNAseq data in *SF3B1^neutral^* and *SF3B1^loss^* cells. Reduced *SF3B1* expression resulted in significantly more alternative 3' splice site selection in *SF3B1^loss^* cells (353 3' splice junctions in *SF3B1^neutral^* vs. 1540 in *SF3B1^loss^* cells, p\<10^−121^, [Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). We also observed other alterations in splicing. Alternative 5' splice site selection occurred at a significantly higher rate upon *SF3B1* suppression in *SF3B1^loss^* cells (1411 junctions vs 317, p=9×10^−165^, [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). We also observed increased dysregulation of cassette exon inclusion. The proportion of reads including the cassette exon at each junction changed substantially after *SF3B1* suppression in *SF3B1^loss^* cells, but was less substantially altered in *SF3B1^neutral^* cells. ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). We further validated these observations with independent assays for alternative splicing. Specifically, the ratio between alternative long and short isoforms of *MCL1* (that respectively do or do not have anti-apoptotic functions) is known to be regulated by SF3B1 ([@bib42]). After *SF3B1* suppression, this ratio was significantly biased towards the short isoform in *SF3B1^loss^* cells relative to *SF3B1^neutral^* cells ([Figure 6D--E](#fig6){ref-type="fig"}). Together, these data indicate that *SF3B1* suppression more substantially dysregulates splicing of the transcriptome of *SF3B1^loss^* cells.

Spliceosome components, including SF3B1, are thought to assemble and function in sub-nuclear compartments known as nuclear speckles ([@bib52]). Inhibition of splicing or transcription has been shown to induce formation of enlarged 'mega-speckles' ([@bib32]; [@bib37]). We therefore performed an unbiased quantification of the number and size of SC-35^+^ speckles per nucleus using a custom image analysis pipeline with CellProfiler software ([@bib30]).

*SF3B1^neutral^* cells did not display changes in SC-35+ speckles after *SF3B1* partial suppression, but *SF3B1^loss^* nuclei contained significantly fewer speckles and increased speckle area ([Figure 6F--H](#fig6){ref-type="fig"}). The presence of defective alternative splicing, intron retention and formation of mega-speckles uniquely in *SF3B1^loss^* cells after partial *SF3B1* suppression further supports the gross defects in splicing observed by RNA sequencing.

Moreover, upon *SF3B1* suppression, 513 genes were differentially expressed at an FDR \< 10% in *SF3B1^loss^* cells and only 306 genes were differentially expressed in *SF3B1^neutral^* cells ([Supplementary file 1E](#SD1-data){ref-type="supplementary-material"}, p\<10^−4^, Fischer's exact test). Gene set enrichment analysis revealed 24 KEGG pathways significantly enriched in *SF3B1^loss^* cells and only nine pathways altered in *SF3B1^neutral^* cells ([Figure 6I](#fig6){ref-type="fig"} and [Supplementary file 1F](#SD1-data){ref-type="supplementary-material"}). We also identified a statistically significant core set of 89 genes differentially expressed across all cell lines upon *SF3B1* suppression regardless of *SF3B1* copy number (p\<10^−4^).

Upon *SF3B1* expression, 348 genes were differentially expressed in *SF3B1^loss^* cells and 393 genes were differentially expressed in *SF3B1^neutral^* cells, an insignificant difference (p=0.07, [Supplementary file 1G](#SD1-data){ref-type="supplementary-material"}). We observed more differentially expressed genes in *SF3B1^loss^* cells from *SF3B1* suppression than from *SF3B1* expression (p\<0.0001), however, there was no difference between the effects of *SF3B1* suppression and expression in *SF3B1^neutral^* lines (p=0.7). Taken together, these data indicate that partial *SF3B1* suppression more severely impacts the transcriptome of *SF3B1^loss^* cells.

Suppression of *SF3B1* reduces tumor growth in *SF3B1^loss^* xenografts {#s2-9}
-----------------------------------------------------------------------

To test the effects of *SF3B1* partial suppression in vivo, we generated xenografts from luciferase-labeled SF3B1^Loss-Cal51-1^, SF3B1^control-Cal51-1^ cells and naturally occurring *SF3B1^neutral^* and *SF3B1^loss^* cells (Cal51 and HCC1954, respectively) all containing TR-shSF3B1\#3. Interventional studies were performed where animals were placed on doxycycline upon detection of palpable tumors and validated for *SF3B1* suppression ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). SF3B1^Loss-Cal51-1^ and SF3B1^control-Cal51-1^ cells generated tumors of similar volume in the absence of doxycycline ([Figure 7A](#fig7){ref-type="fig"}; p=0.7, repeated measures ANOVA). However, partial suppression of *SF3B1* reduced the growth of ([Figure 7B--C](#fig7){ref-type="fig"}) and number of proliferative Ki67+ cells in ([Figure 7D--E](#fig7){ref-type="fig"}) xenografts from SF3B1^Loss-Cal51-1^ cells but not SF3B1^control-Cal51-1^ cells (p=0.001 for both assays). Similarly, reduced tumor growth was observed in naturally occurring *SF3B1^loss^* HCC1954 xenografts and not in *SF3B1^neutral^* Cal51 xenografts ([Figure 7F](#fig7){ref-type="fig"}).10.7554/eLife.23268.015Figure 7.SF3B1 suppression inhibits tumor growth in vivo.Luminescent quantification of xenograft growth from SF3B1^control-Cal51-1^ (black) and SF3B1^Loss-Cal51-1^ (red) tumors (**A**) without doxycycline (n = 4) and (**B**) with doxycycline (n = 17) using TR-shSF3B1 \#3. (**C**) Representative animal images overlaid with heat maps from bioluminescent tumor detection. Dashed circle represents region where established tumor was detected prior to doxycycline treatment. (**D**) Quantification of Ki67+ cells from xenografts 42 days post tumor detection using CellProfiler ≥ 2440 nuclei were scored for each tumor, ≥ 3 tumors per group (see Materials and methods). (**E**) Representative Ki67 immunohistochemistry images of xenografts quantified in panel (**D**). (**F**) Growth of established tumors for Cal51 and HCC1954 xenografts without doxycycline (black) or with doxycycline (red) using TR-shSF3B1 \#3. For Cal51 and HCC1954 no doxycycline groups (n = 13); plus doxycycline groups (n = 12). For all panels, \*\*\*p≤0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.015](10.7554/eLife.23268.015)10.7554/eLife.23268.016Figure 7---figure supplement 1.SF3B1 suppression inhibits tumor growth in vivo.(**A**) Quantitative RT-PCR for *SF3B1* expression from xenograft tumors without (black) or with (red) doxycycline-induced TR-shSF3B1\#3 expression (n≥4 for each group).**DOI:** [http://dx.doi.org/10.7554/eLife.23268.016](10.7554/eLife.23268.016)

Compounds that induce degradation of SF3B1 selectively kill SF3B1^loss^ cells {#s2-10}
-----------------------------------------------------------------------------

The lack of efficacy of small molecule splicing modulators targeting SF3B1 prompted us to evaluate other compounds that could pharmacologically target the SF3B1 CYCLOPS dependency. Deubiquitinase inhibitors (DUBi's) are a class of compounds that increase protein degradation by preventing the removal of ubiquitin from substrates, thereby enhancing target protein degradation by the proteasome. We first sought evidence for SF3B1 ubiquitination by treating cells with the proteasome inhibitor, epoxomicin, to increase the accumulation of ubiquitinated proteins. Immunoprecipitation of SF3B1 in denaturing conditions after epoxomicin treatment resulted in the detection of ubiquitinated SF3B1 ([Figure 8---figure supplement 1A--B](#fig8s1){ref-type="fig"}). Furthermore, proteasome inhibition by MG-132 increased SF3B1 protein levels, suggesting SF3B1 is regulated by the proteasome ([Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}).

To determine if DUBi's could decrease SF3B1 protein expression, we evaluated seven candidate DUBi's for reduced SF3B1 expression by western blot (data not shown) and identified three DUBi's with the ability to reduce SF3B1 protein levels within 24 hr ([Figure 8A](#fig8){ref-type="fig"}). Of the 3 DUBi's that enhance SF3B1 degradation, one semi-selective DUBi b-AP15 ([@bib14]), demonstrated enhanced sensitivity in *SF3B1^loss^* cells, and also cells with reduced *SF3B1* expression by RNAi ([Figure 8B](#fig8){ref-type="fig"}). The enhanced sensitivity in *SF3B1^loss^* cells or cells with reduced *SF3B1* expression by RNAi was not observed upon treatment with SJB3-019A or the pan-DUBi, PR-619 ([Figure 8---figure supplement 1D](#fig8s1){ref-type="fig"}), suggesting inhibition of a specific DUB enzyme may mediate this effect. SF3B1^Loss-Cal51^ cells also had more Annexin V apoptotic cells than SF3B1^control-Cal51^ cells when treated with nanomolar concentrations of b-AP15 ([Figure 8C](#fig8){ref-type="fig"}). Immunoblots for SF3B1 after b-AP15 treatment revealed decreased SF3B1 only occurred in SF3B1^Loss-Cal51-2^ cells ([Figure 8D](#fig8){ref-type="fig"} and [Figure 8---figure supplement 1E](#fig8s1){ref-type="fig"}). These data suggest the enhanced sensitivity may be due, in part, to reduction of SF3B1 in SF3B1^Loss-Cal51^ cells.10.7554/eLife.23268.017Figure 8.Deubiquitinase inhibitor b-AP15 can induce SF3B1 degradation and selectively kill SF3B1^loss^ cells.(**A**) SF3B1 immunoblot after DUBi treatment of the SF3B1^neutral^ cell line, Cal51, at the indicated time points. (**B**) b-AP15 dose response curves in isogenic cell contexts. SF3B1^control-Cal51^ and SF3B1^Loss-Cal51^ or SF3B1^neutral^ cells with or without doxycycline expressing TR-shSF3B1 \#5, to phenocopy the reduced SF3B1 expression observed in SF3B1^loss^ cells, were assayed 48 hr after b-AP15 treatment. (**C**) Percent of Annexin V positive cells 24 hr after b-AP15 treatment in SF3B1^control-Cal51^ and SF3B1^Loss-Cal51^ cells. (**D**) SF3B1 immunoblot 48 hr after treatment with 500 nM b-AP15 in SF3B1^control-Cal51-2^ and SF3B1^Loss-Cal51-2^ cells. (**E**) qPCR for a single intron within the indicated gene with 550 nM b-AP15 or DMSO control (*SF3B1^neutral^* n = 2, *SF3B1^loss^* n = 2, averaged from SF3B1^control-Cal51^ and SF3B1^Loss-Cal51^ cells). (**F**) Schematic of luciferase reporter constructs used in (**G**). Yellow rectangles represent luciferase protein coding regions. Angled black line represents the location of the intron. (**G**) Fold change in luciferase splicing reporter signal after b-AP15 treatment. Data represented as the ratio of spliced luciferase signal (Luc-I) to luciferase ORF signal (Luc-ORF) relative to their respective DMSO luciferase signal. DMSO treatment (black), 350 nM b-AP15 (light red) and 550 nM b--AP15 (dark red). (**H**) b-AP15 dose response in *SF3B1^control^*^-Cal51-2^ and *SF3B1^Loss^*^-Cal51-2^ cells expressing GFP (black) or SF3B1 (blue). For all panels, \*p\<0.05 \*\*p\<0.01 \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.017](10.7554/eLife.23268.017)10.7554/eLife.23268.018Figure 8---figure supplement 1.Deubiquitinase inhibitor b-AP15 can induce SF3B1 degradation and selectively kill SF3B1^loss^ cells.(**A**) SF3B1 immunoprecipitation (IP) under denaturing conditions in the presence of proteasome inhibitor epoxomicin (10 uM) to increase ubiquitinated proteins. (**B**) Silver stain of IP eluate from high stringency conditions in (**A**) to demonstrate the enrichment of SF3B1. (**C**) SF3B1 immunoblot from *SF3B1^neutral^* Cal51 cells 16 hr after treatment with the proteasome inhibitor MG-132 (10 uM). (**D**) Cell titer glo dose response curves for pan-DUBi PR-619 and the more selective DUBi SJB-019A in SF3B1^control-Cal51-1^ and SF3B1^Loss-Cal51-1^ cells. Additional isogenic cell line pairs were generated with or without partial SF3B1 suppression by TRshSF3B1\#5 in SF3B1^neutral^ cells. (**E**) SF3B1 immunoblot in SF3B1^control-Cal51-2^ and SF3B1^Loss-Cal51-2^ cells 24 hr after treatment with 750 nM b-AP15.**DOI:** [http://dx.doi.org/10.7554/eLife.23268.018](10.7554/eLife.23268.018)

Treatment of cells with b-AP15 resulted in splicing alterations preferentially in *SF3B1^loss^* cells. We determined the effect of b-AP15 treatment on previously identified splicing alterations that result from SF3B1 suppression. *SF3B1^loss^* cells but not *SF3B1^neutral^* cells exhibited increased intron retention in *CALR, RPS8 and DNAJB1* after treatment with 550 nM b-AP15 ([Figure 8E](#fig8){ref-type="fig"}). We also generated stable luciferase expressing cell lines with either a luciferase gene interrupted by a chimeric globin/immunoglobulin intron (Luc-I), or a luciferase open reading frame that does not require splicing as a control (Luc-ORF) ([Figure 8F](#fig8){ref-type="fig"}) ([@bib62]). b-AP15 treatment resulted in a dose-dependent decrease in the ratio of Luc-I:Luc-ORF in *SF3B1^loss^*^-Cal51-2^ cells, but not *SF3B1^control^*^-Cal51-2^ cells, suggesting b-AP15 induced SF3B1 degradation may mediate splicing reporter loss of function ([Figure 8G](#fig8){ref-type="fig"}). In contrast, b-AP15 also enhanced *SF3B1^control^*^-Cal51-2^ splicing reporter signal. Lastly, rescue experiments in which we expressed exogenous *SF3B1* increased the concentration of b-AP15 required to impact cell viability in *SF3B1^loss^* cells, but did not affect the sensitivity of *SF3B1^control^*^-Cal51-2^ cells ([Figure 8H](#fig8){ref-type="fig"}).

Taken together, these results suggest that the DUBi, b-AP15, can decrease SF3B1 stability with increased sensitivity in *SF3B1^loss^* cells. They also suggest DUBi's as a potential class of small molecules to be used as a general approach to target candidate CYCLOPS gene dependencies identified here.

Discussion {#s3}
==========

Our analysis indicates that CYCLOPS vulnerabilities are the most enriched class of copy-number associated cancer vulnerabilities, and a focused analysis of this class of vulnerabilities identified 124 candidate CYCLOPS genes. In previous work involving 86 cell lines ([@bib44]), we had identified 55 candidate CYCLOPS genes at a q \< 0.25 significance threshold. Here, we evaluated over twice as many cell lines (179), generating more than twice as many candidate CYCLOPS genes (124) at a more stringent significance threshold (q \< 0.1). We also identified trans gene dependencies associated with copy gain, but the regions of copy gain are often large and contain many genes. As a result, it is difficult to assign a specific gene within the gained region as causing the dependency when gained. Nonetheless these classes of copy number associated gene dependencies warrant further investigation.

Our enhanced ability to detect candidate CYCLOPS genes with larger sample sizes suggests that analysis of additional lines is likely to reveal more candidates. For example, we were unable to identify tumor-type specific CYCLOPS genes due to the relatively small numbers of cell lines screened in each cell lineage. In addition, detection of CYCLOPS vulnerabilities requires partial gene suppression, in which the optimal level of suppression may vary by gene. Among SF3B1 shRNAs, \~50% suppression was achieved. We do not know the extent to which the shRNAs used in Project Achilles matched the required levels to expose CYCLOPS vulnerabilities across other genes. These limitations suggest expanding RNAi viability screens to include more cancer cell lines and shRNAs may yield further CYCLOPS dependencies.

The candidate CYCLOPS genes we identified shared the following features: (1) consistent expression across normal tissues, (2) altered expression when affected by copy-number alterations suggesting lack of feedback regulation, (3) location in genomic regions that frequently undergo copy-loss. These features may predispose genes towards meeting CYCLOPS criteria. However, we cannot exclude the possibility that CYCLOPS genes with different features exist but were not identified due to the limitations of the screening data or analyses.

Components of the spliceosome were the most frequently represented genes among CYCLOPS candidates, with 20 representatives, including *SF3B1*. The spliceosome, which is essential for cell survival, has previously been identified as a therapeutic target in cancer ([@bib29]; [@bib32]; [@bib41]; [@bib59]). Also, the magnitude of *SF3B1* copy-loss required to unveil the SF3B1 CYCLOPS dependency (e.g. single copy loss in a tetraploid cell) will require further study. Our work further substantiates the importance of the spliceosome as a therapeutic target in cancer, and suggests CYCLOPS vulnerabilities as a possible mechanism of dependency.

Mutation of the spliceosome components *SF3B1* and *U2AF1* are recurrent driver events in many cancer types including chronic lymphoblastic leukemia, myelodysplastic syndrome, uveal melanoma and breast cancer ([@bib19]; [@bib24]; [@bib27]; [@bib47]; [@bib58]; [@bib61]). Recent evidence demonstrated that mutations in SF3B1 and SRSF2 can confer preferential sensitivity to chemical modulation of the spliceosome ([@bib35]; [@bib46]). In contrast, we observed partial copy-loss of *SF3B1* and *U2AF1*, likely the result of passenger copy-number alterations, resulted in CYCLOPS vulnerabilities. Consistent with our observations, recent studies of *Sf3b1*^+/-^ mice suggest that partial *SF3B1* loss does not generate haploinsufficient phenotypes ([@bib39]; [@bib56]) in contrast to previous data ([@bib54]). Our observation that ESS1, a *SF3B1^K666N^* mutant cell line, was sensitive to partial SF3B1 suppression is consistent with a prior report that SF3B1*-*mutant cancer cells were found to depend on remaining wild-type copy ([@bib64]). Mutant SF3B1 is also associated with aberrant 3' splice site selection and \~50% rate of nonsense mediated decay in processed transcripts, suggesting that those transcripts exhibit partial loss of function ([@bib15]). Taken together, *SF3B1* mutations may be associated with CYCLOPS dependencies, at least in some cases. Therefore, it is possible that similar approaches to targeting the spliceosome can be exploited in *SF3B1*-mutant and *SF3B1^loss^* cancers. However, it is also possible that alternative strategies will be required for *SF3B1*-mutant and *SF3B1^loss^* cancers, due to their different effects on spliceosome assembly and activity.

We found that partial *SF3B1* suppression is tolerated in *SF3B1^neutral^* cells due to a stable pool of SF3b sub-complex outside of the U2 snRNP. To our knowledge, this is the first observation of such a pool of SF3b, and raises the possibility that SF3b has functions in addition to its role in the U2 snRNP. Precedence exists for such functions as SF3B1 is reported to be a component of the polycomb repressor complex and also directly associates with nucleosomes ([@bib28]; [@bib31]). We also observed decreased protein levels of SNRPB2, SF3A3 and the U2 snRNA in *SF3B1^loss^* cells after *SF3B1* suppression ([Figure 5A and F](#fig5){ref-type="fig"}). It is possible that due to the decreased amount of assembled 17S U2 snRNP, the U2 precursor complexes are less stable and degraded to maintain proper U2 snRNP stoichiometry in *SF3B1^loss^* cells. Although these experiments were performed prior to detection of apoptosis, we cannot exclude the possibility that decreased U2 precursor complexes are a result of decreased cell viability beyond the level of detection.

Small molecule inhibitors of SF3B1, and the spliceosome in general, are an emerging class of anti-neoplastic agents. The finding that many candidate CYCLOPS genes are splicing factors suggests further efforts should be paid to identifying CYCLOPS vulnerabilities that can be exploited by spliceosome inhibitors.

In the case of *SF3B1*, we find that *SF3B1* copy-loss reduces the levels of the SF3b complex, but not assembled U2 snRNP, which suggests that inhibitors of the assembled U2 snRNP will not adequately distinguish between *SF3B1^loss^* and *SF3B1^neutral^* cells. This includes most current inhibitors of SF3B1 ([@bib12]; [@bib20]; [@bib49]). Understanding which SF3B1 complexes are bound by these compounds, and how they affect the stability, assembly, or function of the U2 snRNP, will be important to glean mechanistic insight into the landscape of small molecule modulation of SF3B1.

More generally, many CYCLOPS vulnerabilities are unlikely to be exploited by compounds that directly inhibit CYCLOPS gene enzymatic activity. Most of the candidate CYCLOPS genes we identified are not enzymes. Many of them are components of multi-protein complexes. One approach to exploiting these vulnerabilities may be to disrupt the incorporation of the proteins encoded by such CYCLOPS genes into these larger complexes. Another approach may be to reduce levels of protein encoded by CYCLOPS genes, either by interfering with the transcription of these genes ([@bib2]; [@bib34]) or by enhancing protein degradation ([@bib7]; [@bib14]; [@bib60]). An advantage to CYCLOPS targets such as SF3B1 is that only moderate (\~50%) reductions in protein levels need to be achieved to take advantage of the vulnerability.

Finally, we evaluated DUBi's as a potential small molecule to target the SF3B1 CYCLOPS vulnerability. We found that the DUBi b-AP15 could reduce SF3B1 protein levels and preferentially target SF3B1^loss^ cells. A derivative of b-AP15, VLX1570, is already in use in humans (Trial ID: NCT02372240). Our results indicate SF3B1 copy number should be tested as a potential biomarker of response for patients treated with this compound.

Although b-AP15 specifically suppressed growth of cells with loss of SF3B1, it is possible other DUBi's would be even more specific. There are approximately 90 DUBs in humans ([@bib45]), and the DUBi's we tested are relatively non-selective. Further investigation of the specific DUBs that support SF3B1 protein expression would enable identification DUBi's whose effects are more targeted to the SF3B1 dependency.

The finding that a DUBi specifically suppresses growth of cells with loss of SF3B1 also supports the use of DUBi's to target any of the 124 candidate CYCLOPS genes we identified, representing a potential paradigm for treating cancers based upon non-oncogenic genetic events.

Materials and methods {#s4}
=====================

Analysis of genome-wide copy-number associated cancer dependencies {#s4-1}
------------------------------------------------------------------

Gene-level relative copy-numbers were downloaded from the CCLE portal (<http://www.broadinstitute.org/ccle>, data version 4/06/2012) totaling 23,124 genes. Gene-level dependencies were obtained for 214 cell lines from Project Achilles (version 2.4.3). Of the 214 cell lines, only 179 had corresponding copy-number data and were used for subsequent analyses. ATARiS gene dependency scores were used to estimate the effect of shRNA-induced gene suppression on cell viability ([@bib51]) totaling 8724 gene dependencies. Pearson correlation coefficients and associated p-values were calculated for the association of viability after suppression of each gene with the copy number of all genes. P-values were corrected for multiple hypotheses using the Benjamini-Hochberg method ([@bib4]). We considered associations between copy-numbers of every gene in the genome and dependencies of every gene with ATARiS scores. Large copy-number events affecting many neighboring genes often generated identical significant copy-number:gene dependency associations for copy-numbers associated with multiple genes. We considered these to reflect a single gene whose copy-number was responsible for the association. When the gene dependency was one of the genes contained within the copy-number altered region, we nominated that gene as the source of the association. Likewise, if a gene dependency reflected a paralog of a gene within the copy-number altered region, we nominated its paralog as the dependency-associated gene within the altered region.

CYCLOPS analysis {#s4-2}
----------------

We determined the significance of differences in ATARiS scores between copy-neutral and --loss lines for every gene by comparing the observed data to data representing random permutations of copy-number class labels, each maintaining the number of cell lines and lineage distribution in each class. Copy-number classes were assigned as copy-loss for cells with log~2~ relative copy number ratios ≤ −0.35 and copy-neutral otherwise. Genes for which fewer than two cell lines exhibited copy loss were excluded from the analysis.

Generation of heterozygous *SF3B1^loss^* cells by CRISPR-Cas9 {#s4-3}
-------------------------------------------------------------

For SF3B1^Loss-Cal51-1^ cells, sgRNAs targeting the first constitutively expressed coding exon of *SF3B1* (exon 2) were designed with the aid of a web-based application (<http://crispr.mit.edu/>). Sense and anti-sense oligonucelotides were annealed and cloned into *BbsI* site of pX458 (Addgene) and verified by Sanger sequencing. Single GFP+ cells were sorted by FACS and plated at low density for single cell cloning. SF3B1^control-Cal51-1^ cells were processed identically, but did not have inactivating *SF3B1* mutations. (See supplementary information for further details.)

For SF3B1^Loss-Cal51-2^ cells, a Cas9 construct co-expressing two sgRNAs and GFP was used to delete a 57 kb region encoding *SF3B1*. The guide RNA targeting the 5' upstream of *SF3B1* used a mismatch from a heterozygous SNP (rs3849362) in Cal51 to bias towards mono-allelic deletion of *SF3B1*. Single GFP+ cells were plated as described above and expanded. One of these was validated by PCR to harbor a 57 kb deletion encoding SF3B1. This was designated 'SF3B1^Loss-Cal51-2^' for subsequent experiments. Another one of these was found by PCR not to harbor this deletion and was designated as the control cell line for subsequent experiments ('SF3B1^control-Cal51-2^').

Glycerol gradient sedimentation {#s4-4}
-------------------------------

Glycerol gradient sedimentation was performed as previously described ([@bib26]) with slight modifications for use with whole-cell lysates. Briefly, 10--30% glycerol gradients were formed by layering 10% glycerol gradient buffer (20 mM Hepes-KOH (pH 7.9), 150 mM NaCl, 1.5 mM MgCl~2~10% glycerol) on top of a 30% glycerol buffer with identical salt concentrations. Gradients were formed using a Gradient Station (Biocomp Instruments). Cells were lysed in 'IP lysis buffer' (50 mM Tris, 150 mM NaCl and 1% Triton X-100). 400 uL containing 1--3 mg of crude lysate was loaded per gradient in SW55 centrifuge tubes and spun at 55,000 RPM for 3.5 hr at 4C. A total of 25 200 uL fractions were collected by manually pipetting from the top of the gradient. Recombinant proteins of known mass were run in parallel gradients as controls.

Gel filtration chromatography {#s4-5}
-----------------------------

Sephacryl S-500 (17-0613--05, GE Healthcare) columns were packed into a 50 × 1.5 cm column and equilibrated with column buffer (10 mM Tris, 60 mM KCl, 25 mM EDTA, 1% Triton X-100 and 0.1% sodium azide). Whole-cell lysates were collected in IP lysis buffer as described above and incubated with 0.5 mM ATP, 3.2 mM MgCl~2~ and 20 mM creatine phosphate (di-Tris salt) for 20 min at 30C to dissociate multi-snRNP spliceosomal complexes. 2 mL of lysate containing 5 mg of protein was loaded on columns and 90 1.5 mL fractions were collected overnight at 4C.

RNA sequencing analysis {#s4-6}
-----------------------

Total RNA was extracted and treated by DNAse digestion. RNA quality was determined by bioanalyzer (Agilent) and samples with RIN values \>7 were used for sequencing. mRNAs were enriched with the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England BioLabs, \#E7490S) and library preparations were performed with the NEBNext Ultra Directional RNA Library Prep Kit (New England BioLabs, \#E7420S). 75 bp paired reads were generated using a NextSeq 500 sequencer (Illumina). Approximately 50 million reads per sample were generated. FASTQ files were aligned using TOPHAT v1.4 with parameters '\--mate-inner- dist 300 \--mate-std-dev 500 \--no-sort-bam \--no-convert-bam -p 4'. JuncBase was used to identify read counts at splice junctions (see Appendix Methods).

Generation of xenografts and growth assessment {#s4-7}
----------------------------------------------

All animal husbandry was done with the approval of the Dana-Farber Cancer Institute IACUC. 1 × 10^6^ SF3B1^control-Cal51-1^ or SF3B1^Loss-Cal51-1^ cells expressing TR-shSF3B1 \#3 were subcutaneously injected into opposing flanks of nude mice (*Foxn1 ^nu/nu^*, Harlan). Animals were randomized to control group or doxycycline treatment after detection of a palpable tumor on either flank. Mice in the doxycycline treatment arm were continuously fed a doxycycline diet (2000 ppm). Mice were sacrificed at the end of the experiment, or when endpoints were reached based on failure to thrive according to IACUC recommendation. Repeated measures two-way ANOVA was used to assess significance.
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###### Supplementary tables.

\(A\) Results of copy-number associated dependencies. (B) Results of CYCLOPS gene analysis. (C) Frequency of genetic *SF3B1* alterations in cancer. (D) KEGG Pathways Enriched from significant candidate CYCLOPS genes. (E) Significantly differentially expressed genes after *SF3B1* suppression in *SF3B1^neutral^* and *SF3B1^loss^* cells. (F) Summary of KEGG pathway enrichment from differentially expressed genes in each class (*SF3B1^loss^* or *SF3B1^neutral^*) from genes in Supplementary file E. (G) Significantly differentially expressed genes after enhanced SF3B1 expression. (H) PCR primer sequences used in this study.
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Major datasets {#s7}
--------------

The following dataset was generated:

Paolella B,Gibson W,2016,Effect of SF3B1 suppression in cancer cells with different SF3B1 copy-number levels,<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81978>,Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE81978)

The following previously published dataset was used:

Cowley GS,Weir BA,Vazquez F,Tamayo P,Scott JA,Rusin S,East-Seletsky A,Ali LD,Gerath WFJ,Pantel SE,Lizotte ph,Jiang G,Hsiao J,Tsherniak A,Dwinell E,Aoyama S,Okamoto M,Harrington W,Gelfand E,Green TM,Tomko MJ,Gopal S,Wong TC,Li H,Howell S,Stransky N,Liefeld T,Jang D,Bistline J,Meyers BH,Armstrong SA,Anderson KC,Stegmaier K,Reich M,Pellman D,Boehm JS,Mesirov JP,Golub TR,RootDE,Hahn WC,2014,Project Achilles,<https://portals.broadinstitute.org/achilles/datasets/5/download>,Publicly available at the Broad Institute Project Achilles Data Portal, version 2.4.3 (https://portals.broadinstitute.org/achilles)

 {#s25}

We use the following definitions:

Somatic copy-number alterations (SCNAs):

Somatic changes in the number of copies of a DNA sequence that are observed in cancer cells but not their paired germline DNA.

Gene dependency:

A gene whose suppression results in a loss of fitness for a particular cell context.

Copy-number associated gene dependency:

A gene dependency among cells that share a copy-number alteration at a given locus. In the case of cancer, most of these copy-number alterations will be somatic (SCNAs).

We also distinguish between the following classes of copy-number associated gene dependencies:

1.  Cis copy-number associated gene dependencies: Here, the dependency on a gene is associated with the copy number of that gene. This can take two forms:Cancer cells can be especially vulnerable to suppression of a gene when it is amplified. This class of dependencies comprises oncogene addiction-induced dependencies, which result from amplifications of a target gene whose increased expression is important in maintaining cancer cell survival. One example is EGFR amplifications in lung cancer.Cancer cells can depend on a gene within a region of partial copy loss. For this class, reduced copy-number of the gene imparts sensitivity to further suppression of that same gene. This is the CYCLOPS (Copy-number alterations Yielding Cancer Liabilities Owing to Partial losS) class.

2.  Trans copy-number associated gene dependencies: Here, the dependency on a gene is associated with the copy number of a different gene.Amplifications of a region can impart sensitivity to suppression of a gene outside the gained region. Currently, we know of no genes in this class.Copy loss of a gene can impart sensitivity to suppression of a different gene. Such dependencies can occur if deletion of one gene from a paralogous pair of genes renders cells sensitive to suppression of the remaining paralog.

Supplemental experimental procedures {#s26}
====================================

Classification of length and amplitude for copy number alterations {#s27}
------------------------------------------------------------------

For relative log~2~ normalized copy number data analyzed from 10,570 tumors from TCGA ([@bib63]), the following thresholds were used for copy number classification: homozygous loss log~2~values \<−1.2, hemizygous loss log~2~ ≤ −0.35. For cancer cell lines used in functional studies: copy-loss cells had log~2~ copy number ≤ −0.35, and copy neutral cells had log~2~ copy number \>−0.2 and \<0.2.

Analysis of the location of CYCLOPS genes on chromosome arms with known tumor suppressors {#s28}
-----------------------------------------------------------------------------------------

Deleted tumor suppressor genes were obtained from the combined lists from previous studies ([@bib6]; [@bib63]). Among 8131 genes assessed by Achilles, 5546 were on chromosome arms with at least one deleted tumor suppressor gene, including 73 of the 124 candidate CYCLOPS genes. A two-sided Fisher's exact test was used to determine the significance of enrichment of CYCLOPS genes on arms shared with tumor suppressors.

Analysis of candidate CYCLOPS gene and their overlap with [@bib38] shRNA viability screen {#s29}
-----------------------------------------------------------------------------------------

A complete list of genes analyzed for increased sensitivity upon partial copy loss was kindly shared by Azin Sayad and Benjamin Neel \[see Table S6C in [@bib38]. A total of 8008 genes were analyzed in both studies, including 103 of the 124 candidate CYCLOPS genes we identified. We used the authors' determinations of which genes exhibited statistically significant associations between dependency and copy loss, taking p\<0.05 as the significance threshold. The overall significance of overlap between candidate CYCLOPS genes in our study and ([@bib38]) was determined using a Fisher's Exact test with a two-sided p-value.

Analysis of gene expression across normal tissues {#s30}
-------------------------------------------------

RNA sequencing data were downloaded from the GTEX database (<http://www.gtexportal.org/home/>). For every gene in the genome, we calculated the expression variance across all samples and ranked the variance against the 20 genes with the most similar average expression level. These ranks served as a nearest-neighbors normalized measure of expression variance.

Tissue culture {#s31}
--------------

Human cancer cell lines were maintained in RPMI-1640 supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin and were assayed to be free of mycoplasma. Non-transformed MCF10A and HMEC cells were cultured in Mammary Epithelial Growth Medium (CC-3150, Lonza). For cells expressing tetracycline-regulated shRNAs, tetracycline-approved fetal bovine serum (Clonetech) was used. Cell lines were original purchased from ATCC or DSMZ. All cell line identities were confirmed using genetic profiling using polymorphic short tandem repeat (STR) loci at the Dana-Farber molecular diagnostics laboratory. No commonly misidentified cell lines defined by the International Cell Line Authentication Committee have been used in these studies.

Correlation analysis of copy-loss of SF3b genes with cell dependencies upon suppression of other SF3b complex genes {#s32}
-------------------------------------------------------------------------------------------------------------------

We determined the relative copy number and ATARiS gene dependency scores after knockdown of each SF3b complex member across the same 179 cell lines used in the CYCLOPS analysis. We performed linear regression analysis for copy number of each SF3b complex gene with knockdown of every SF3b component. One-sided p-values were calculated for association of sensitivity to suppression with gene loss for all intra-SF3b complex comparisons. Samples were excluded if they harbored co-deletion of the two genes used to generate the correlation.

Quantitative and reverse transcription PCR {#s33}
------------------------------------------

RNA was extracted using the RNeasy extraction kit (Qiagen) and subjected to on-column DNase treatment. cDNA was synthesized with the Superscript II Reverse Transcriptase kit (Life Technologies) with no reverse transcriptase samples serving as negative controls. Gene expression was quantified by Power Sybr Green Master Mix (Applied Biosystems). Primers for all genes were determined to be equally efficient over five serial two-fold dilutions. Gene expression values were normalized to *ACTB* and the fold change calculated by the ΔΔC~t~ method. For quantification of the U2 snRNA, the above method was used except total cellular RNA was extracted with Trizol (Life Technologies). For primer sequence information see [Supplementary file 1H](#SD1-data){ref-type="supplementary-material"}.

shRNAs targeting SF3B1 {#s34}
----------------------

Lentiviral expression constructs for shRNA-mediated suppression of *SF3B1* were obtained through the RNAi-consortium (<http://www.broadinstitute.org/rnai/public/>). The clone ID's and names used in our studies are as follows: shSF3B1 \#2 (TRCN0000320576), shSF3B1 \#3 (TRCN0000320566), shSF3B1 \#4 (TRCN0000350273), shSF3B1 \#5 (TRCN0000320636). For PHF5A, the clone ID's and names used were: shPHF5A-78 (TRCN0000074878) and shPHF5A-79 (TRCN0000074879). For constitutive and inducible vectors, we respectively used the pre-existing control hairpins shLacZ and shLuciferase ([@bib44]).

Generation of Inducible *SF3B1* shRNA expression system. {#s35}
--------------------------------------------------------

Sense and anti-sense oligonucleotides were annealed and cloned into the *AgeI* and *EcoRI* restriction sites of the pLKO-Tet-puro vector (Addgene, plasmid \#21915). The oligonucleotide sequences were:

TR-shSF3B1\#3 (sense) 5'- CCGGCAACTCCTTATGGTATCGAATCTCGAGATTCGATACCATAAGGAGTTGTTTTTG,

TR-shSF3B1\#3 (anti-sense) 5'- AATTCAAAAACAACTCCTTATGGTATCGAATCTCGAGATTCGATACCATAAGGAGTTG,

TR-shSF3B1\#5 (sense) 5'-CCGGCCTCGATTCTACAGGTTATTACTCGAGTAATAACCTGTAGAATCGAGGTTTTTG,

TR-shSF3B1\#5 (anti-sense) 5'-AATTCAAAAACCTCGATTCTACAGGTTATTACTCGAGTAATAACCTGTAGAATCGAGG

Additional information for the generation of heterozygous *SF3B1^loss^* cells by CRISPR-Cas9 {#s36}
--------------------------------------------------------------------------------------------

Oligonucleotide sequences for SF3B1^Loss-Cal51-1^ were as follows: 5' CACCGCATAATAACCTGTAGAATCG (forward), 5'AAACCGATTCTACAGGTTATTATGC (reverse). pX458 was transfected with LipoD293 (SignaGen) into the diploid breast cancer cell line, Cal51.19 monoclonal cell lines were genotyped for Cas-9 induced mutations by Sanger sequencing cloned PCR products. All monoclonal lines had either no mutations or harbored biallelic mutations in *SF3B1*. The genotypes of the Cal51 CRISPR cell lines used from this method of generation were: *SF3B1^delT36/delT36^* (SF3B1^control-Cal51-1^) and SF3B1^delT36/A23fsX20^ (SF3B1^Loss-Cal51-2^). Copy number profiles from the two lines were characterized by SNP array. No SCNAs were detected as a result of single cell cloning (data not shown).

Oligonucleotides for SF3B1^Loss-Cal51-2^ cells were cloned in a similar fashion as SF3B1^Loss-Cal51-1^ in pX458 (with BbsI overhangs). The sequences are as follows: For the 5' guide targeting SNP, 5' CACCGCGCATTATAGATTATGGCCC (forward) and 5' AAACGGGCCATAATCTATAATGCGC (reverse). For the 3' targeting guide: 5'CACCGCGGAGTTTCATCCGTTACAC (forward), AAACGTGTAACGGATGAAACTCCGC (reverse)

Cellular growth assays {#s37}
----------------------

Cells were plated in 96 well plates at 1000 cells per well. Cell number was inferred by ATP-dependent luminescence by Cell Titer Glo (Promega) and normalized to the relative luminescence on the day of plating. For short-term lentiviral infections, cells were infected 24 hr prior to plating. Relative proliferation was calculated as the fold change in ATP luciferase luminescence units from Cell Titer Glo assays relative to shLacZ expressing cells seven days after shRNA infection ([Figure 3G](#fig3){ref-type="fig"}).

GFP competition assays {#s38}
----------------------

Oligonucleotides encoding *LacZ* or *SF3B1* shRNA\#4 hairpin sequences were annealed and cloned into the pLKO.1 derivative vector TRC047 (pLKO.3pgw) and verified by Sanger sequencing. Cells were infected with serial dilutions of virus to achieve \~50% GFP-positive cells. Cells with approximately equivalent ratios of GFP-positive and negative cells were assayed by flow cytometry 3 days post infection and at subsequent time-points. The fold change in GFP+ cells was normalized to the percentage present 3 days after infection. For competition assays re-introducing exogenous *SF3B1*, we expressed a human codon-optimized *SF3B1* by lentivirus. Cells were infected as described above and treated with doxycycline two days after infection.

Propidium iodide cell viability assays {#s39}
--------------------------------------

Cells were treated with either short-term lentiviral infection or tetracycline-inducible *SF3B1* shRNAs. After treatment, cells were trypsinized and pelleted including any cells in suspension. Cells were resuspended in propidium iodide viability staining solution (1x PBS, 1% BSA, 2.5 ug/mL propidium iodide) and quantified by live-cell flow cytometry. The change in viability was normalized to the percent of viable cells quantified on the first day of the assay.

Determination of cell cycle distribution by propidium iodide {#s40}
------------------------------------------------------------

Cells were trypsinized, washed, and fixed with ice-cold 70% ethanol for a minimum of 15 min at 4C. Cells were incubated in propidium iodide cell cycle staining solution (1x PBS, 1% BSA, 50 ug/mL propidium iodide, 100 ug/mL RNAse A) for 15 min and analyzed by flow cytometry. Debris and aggregates were gated out and cell cycle stage was quantified using Modfit (Varity Software House).

Annexin-V apoptosis assays {#s41}
--------------------------

Cellular apoptosis was quantified by live-cell flow cytometry using Alexa-Fluor 488 conjugated Annexin-V (Life Technologies) and propidium iodide. Cells were incubated in Annexin binding buffer containing propidium iodide (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl~2~, 2.5 ug/mL propdium iodide) for 15 min, washed and resuspended in FACS buffer (1x PBS, 1% BSA and 50 mM EDTA). Determination of the stage of apoptosis by gating was as follows: viable cells (Annexin-V^−^/PI^−^), early apoptosis (Annexin-V^+^/PI^−^), late apoptosis (Annexin-V^+^/PI^+^), and dead cells (Annexin-V^−^/PI^+^).

Western blotting {#s42}
----------------

For denaturing protein immunoblots, cells were washed in ice cold PBS and lysed in 1x RIPA buffer (10 mM Tris-Cl Ph 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% SDS and 140 mM NaCl) supplemented with 1x protease and phosphatase inhibitor cocktail (PI-290, Boston Bioproducts). Lysates were sonicated in a bioruptor (Diagenode) for 5 min (medium intensity) and cleared by centrifugation at 15000 x g for 15 min at 4C. Proteins were electrophoresed on polyacrylamide gradient gels (Life Technologies) and detected by chemiluminescence. For native western blotting, cells were washed in ice cold PBS and lysed in 1x sonication buffer (10% Glycerol, 25 mM HEPES pH 7.4, 10 mM MgCl~2~) supplemented with protease and phosphatase inhibitors. Coomassie blue native PAGE western blots were run according the manufacturer's instructions (Life Technologies).

Quantification of western blots by densitometry {#s43}
-----------------------------------------------

Immunoblot exposures were quantified using ImageJ ([@bib50]) as previously described (<http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-image-j/>). For early glycerol gradient fractions, pixel density histograms and an area under the curve (AUC) were calculated for each western blot band. Each western band AUC was normalized relative to loading control AUCs and then expressed as the fold change relative to glycerol fraction \#3 (for [Figure 4F](#fig4){ref-type="fig"}). A minimum of 2 technical replicates per cell line (range 2--5) were performed for each of three *SF3B1^neutral^* and *SF3B1^loss^* cell lines. For [Figure 3E](#fig3){ref-type="fig"} and S6B-D, loading control normalized AUCs were expressed as the fold change relative to the diploid Cal51 cell line.

SF3B1 gene expression analysis from TCGA and CCLE datasets {#s44}
----------------------------------------------------------

Relative copy number and Affymetrix expression data for *SF3B1* were downloaded from the CCLE portal (<http://www.broadinstitute.org/ccle/home>). TCGA breast adenocarcinoma data were downloaded from the cBioPortal (<http://www.cbioportal.org/public-portal/index.do>) ([@bib10]; [@bib22]). For both datasets, samples lacking either gene expression or copy-number were removed. As described above, copy-loss was defined as samples with log~2~ normalized relative copy number of \<−0.35, copy gain was defined as ≥ 0.3.

Spliceosome and DUBi drug viability assays {#s45}
------------------------------------------

Cells were plated in 96 well plates at 10,000 cells per well. Relative viability was calculated as the fold change in ATP luciferase luminescence units from Cell Titer Glo assays relative to DMSO treated cells 48 hr after drug treatment ([Figure 5---figure supplement 1F](#fig5s1){ref-type="fig"}, [Figure 6H--I](#fig6){ref-type="fig"}, [Figure 8B,H](#fig8){ref-type="fig"} and [Figure 8---figure supplement 1D](#fig8s1){ref-type="fig"}).

Immunoprecipitation {#s46}
-------------------

Immunoprecipitations were performed with pooled glycerol gradient fractions. The Fc region of mouse anti-SF3B1 (Medical and Biological Laboratories, D221--3) was directionally cross-linked to protein G Dynabeads (Life Technologies) using 20 mM dimethyl pimelimidate (DMP). IgG isotype controls were cross-linked and processed identically. Proteins were eluted with elution buffer (15% glycerol, 1% SDS, 50 mM tris-HCl, 150 mM NaCl pH 8.8) at 80C and subjected to western blot analysis.

U2 snRNA 2' O-methyl oligonucleotide assays {#s47}
-------------------------------------------

2' O-methyl oligonucleotides complementary to the branchpoint binding region of the U2 snRNA were synthesized by Integrative DNA Technologies with the following sequences:

(Branchpoint oligo) 5'mCmAmG mAmUmAmCmUmAmCmAmCmUmUmGmA,

(control oligo) 5'mAmCmUmGmUmAmCmUmAmAmCmUmGmAmCmUmG.

Experiments were performed as described in ([@bib21]). Briefly, mini nuclear extracts from SF3B1^control-Cal51^ and SF3B1^Loss-Cal51^ cells were generated using standard protocols ([@bib21]). U2 snRNA-targeting and control oligos were radiolabeled with ^32^P-gamma ATP with T4 polynucleotide kinase. ATP was depleted from all extracts by incubation at RT for 20 min. 300 ug of total protein from nuclear extracts were added to 25 uL reaction mixtures with or without 0.5 mM ATP, 3.2 mM MgCl~2~, and 20 mM creatine phosphate (di-Tris salt). Reactions were incubated at 30C of 5 min before adding 34 ng of either branchpoint-targeting or control oligo and subsequent incubation for another 5 min at 30C. For reactions without ATP, water was used to raise the volume to 25 uL. Samples were purified on microspin G-50 columns (GE) and loaded in a 1.2% low-melting agarose gel.

Nuclear speckle quantification by SC-35 immunofluorescence with CellProfiler image analysis {#s48}
-------------------------------------------------------------------------------------------

Cells were plated on 35 mm glass bottom dishes with \#1.5 cover glass (D35-14--1.5 N, In Vitro Scientific). Cells were fixed and stained with anti-SC-35 antibody (S4045, Sigma-Aldrich) at 1:1000 dilution and detected with Alexafluor488 secondary antibody at 1:1000 (Life Technologies). Nuclei were counterstained with Hoescht dye. Monochromatic images were captured under identical conditions and pseudo-colored using Photoshop. A custom image analysis pipeline was empirically adapted from a pre-existing pipeline designed for detecting H2AX foci using CellProfiler ([@bib30]). Measurements of nuclear speckles were generated from at least 15 random microscopic fields. A minimum of 100 nuclei identified by CellProfiler were used for quantitation per treatment.

Ki67 quantification from tumor xenografts {#s49}
-----------------------------------------

A custom image analysis pipeline was used to systematically quantify Ki67+ cells from tumor xenografts using CellProfilier. A minimum of 3 tumors per group, totaling at least 2440 nuclei per tumor, was used to quantify the ratio of Ki67+ cells. At least five individual and random microscopic images from each tumor were analyzed.

Luciferase splicing reporters {#s50}
-----------------------------

CMV-LUC2CP/intron/ARE (Luc-I in this manuscript, Addgene plasmid \# 62858) and CMV-LUC2CP/ARE (Luc-ORF in this manuscript, Addgene plasmid \# 62857) were gifts from Gideon Dreyfuss ([@bib62]). Cells were transfected and hygromycin selected to generate stable cell lines. Cells were then treated with b-AP15 and assayed for luciferase luminescence 24 hr after treatment with the Luciferase Assay System kit (Promega). The fold change in splicing was calculated as the ratio of Luc-I to Luc-ORF after normalizing to DMSO treatment.

RNAseq analysis of splicing by juncBase and beta binomial distribution {#s51}
----------------------------------------------------------------------

To identify common splicing alterations across cancer cell lines, we conducted the RNAseq splicing analyses ([Figure 6A and C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1D. ](#fig6s1){ref-type="fig"}only in the patient derived cells lines. This was done to avoid overweighting the Cal 51 cell line from which the isogenic system was generated. We then validated samples for intron retention in both isogenic cells and those with naturally occurring copy number alterations in SF3B1 ([Figure 6B](#fig6){ref-type="fig"}).

JuncBASE was used to determine the spliced in/spliced out counts at each splice junction. In the following section we will use intron retention as the example for the way our beta binomial statistic works. The spliced in/spliced out counts at each junction were used to create an estimate of the percent of transcripts with the intron retained (Percent Spliced In, where the intron refers to the inclusion isoform; PSI) for each cell line. We estimated the distribution of this statistic for each cell line in each condition (with and without *SF3B1* suppression) using a beta binomial distribution in which spliced in and spliced out read counts were the α and β terms, respectively. Because we only observe a finite number of reads across the junction, the PSI obtained by simple division may not be accurate. We capture the extent of this inaccuracy by calculating an estimate of the probability distribution of the true PSI, given the read counts observed. The beta binomial distribution is used in cases like this where one is attempting to obtain an estimate of the distribution of a Bernoulli random variable (true PSI) from a set of observations of trials and successes. The PSI (IR) for cell line i at intron j, is therefore estimated as:$$IR_{i,j} = Beta\left( \alpha_{i,j},\beta_{i,j} \right)$$

Where $\alpha = n_{reads~intron~j~retained~in~cell~line~i}$ and $\beta = n_{reads~intron~j~excised~in~cell~line~i}$

We then sought to quantify the probability distribution of the ratio of PSI's (PSIR) in the same cell line upon SF3B1 suppression. This ratio corresponds to the relative probability of retaining intron j in cell line i, upon SF3B1 suppression. We base this calculation on the two distributions:$$IR_{i,j,no~SF3B1~suppression} = Beta\left( \alpha_{i,j,~no~SF3B1~suppression},\beta_{i,j,no~SF3B1~suppression} \right)$$$$IR_{i,j,~with~SF3B1~suppression} = Beta\left( \alpha_{i,j,with~SF3B1~suppression},\beta_{i,j,with~SF3B1~suppression} \right)$$

We extend the following intuition concerning ratio distributions:$$P\left( Z \right) = \int\limits_{0}^{1}\int\limits_{0}^{1}\frac{X}{Y}\ P(X)\ P(Y)\ dX\ dY$$

where Z=X/Y and X and Y are independent and distributed between 0 and 1.

In this case, the relative risk of including an intron for cell line i and intron j is:$$PSIR_{i,j} = \frac{IR_{i,j,~with~SF3B1~suppression}}{IR_{i,j,no~SF3B1~suppression}}$$

$P\left( {PSIR_{i,j}} \right) = \int\limits_{0}^{1}\int\limits_{0}^{1}\frac{X}{Y}\ P\left( x \right)\ P\left( y \right)\ dx\ dy$ where $x = ir_{i,j,~with~SF3B1~suppression}$ and $y = ir_{i,j,\ no\ SF3B1\ suppression}$

This integral can be calculated exactly ([@bib48]), by bootstrapping, or by approximation with a discrete distribution. We used the latter approach due to issues with numeric overflow in calculating the exact distribution and the computational inability to perform fine enough sampling to obtain very small p-values (ie \<10^−9^) using bootstrapping. To compute the discrete approximation, we iterated through a discrete set of PSI ratios spaced between 0.01 and 100. During each iteration, we calculated the joint distribution of $z_{i,j}$=x/y as above (where $z_{i,j}$ = $\left. PSIR_{i,j} \right).~~$We sampled x ($IR_{i,j,~with~SF3B1~suppression}$) at 1000 intervals between 0 to 1 and calculated the set of y's ($IR_{i,j,~no~SF3B1~suppression}$) such that y=x/z. We then calculated the joint probability of x and y for all x,y combinations and summed these values to calculate the probability of observing a given relative risk $z_{i,j}$. The discrete probability distribution of $z_{i,j}$ was then normalized to 1 to achieve the final probability distribution on the PSI ratio for intron j in cell line i upon SF3B1 suppression.

A posterior estimate of the probability distribution of the PSI ratio in SF3B1^loss^ cell lines $\left( {PSIR_{SF3B1loss}} \right)$was then obtained by a point-wise multiplication of the distributions $PSIR_{i,j}$$$PSIR_{SF3B1loss}\left( x \right)~ \propto ~~\prod^{}PSIR_{i,j}$$

for all cell lines with the genotype SF3B1^loss^. The same procedure was used to calculate the posterior estimate of the PSI ratio for intron retention in SF3B1^neutral^ cell lines $PSIR_{SF3B1neutral}$.

Finally, we calculated the p-values for the difference between the distributions $PSIR_{SF3B1loss}$ and $PSIR_{SF3B1neutral}$. This p-value represents the area of overlap of the two distributions and can be obtained by integrating proportion of the convolution of the $PSIR_{SF3B1loss}$ and $PSIR_{SF3B1neutral}$ that is greater than 0.$$P(nh) = \int\limits_{0}^{\infty}\left\lbrack {PSIR_{SF3B1loss} \ast - PSIR_{SF3B1neutral}} \right\rbrack$$

Where $P\left( {nh} \right)$ is the probability of the null hypothesis that the true values of $PSIR_{SF3B1loss}$ and $PSIR_{SF3B1neutral}$ are equal. Multiple hypothesis correction was performed using the Benjamini-Hochberg method ([@bib4]).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability\" for consideration by *eLife*. Your article has been favorably evaluated by Charles Sawyers (Senior Editor) and three reviewers, one of whom, Michael R Green (Reviewer \#1), is a member of our Board of Reviewing Editors. One other reviewer, Robert K Bradley (Reviewer \#3), has agreed to reveal his identity.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is an interesting manuscript which identifies that cancer cells with partial copy number loss of essential genes appear to be preferentially sensitive to further depletion of these genes. These so-called CYCLOPS genes appear to be enriched in genes encoding essential proteins, including spliceosomal proteins. The authors focus on cells with copy number loss of SF3b1 and suggest that these cells are more sensitive to loss of SF3B1. This is an exciting result because it potentially expands the number of malignancies that could be treated with SF3B1 inhibitors. The experiments are generally well performed but some clarifications as described below would help improve the study as listed below. The greatest weakness of the paper is that the specificity of the deubiquitinase inhibitor for SF3B1 is not clear and the efficacy of SF3B1 binding drugs in SF3B1 partial loss cells should be studied in more detail.

Essential revisions:

1\) It is unclear in [Figure 5](#fig5){ref-type="fig"} if partial copy number of loss of SF3B1 reduces levels of U2 snRNP and/or if this occurs only following further depletion of SF3B1. It is also not clear why partial reduction of SF3b1 would reduce expression of other U2 snRNP components and U2 snRNA (unless the cells experience reduce levels of these components simply due to reduced viability upon further SF3B1 suppression).

2\) The lack of efficacy of SF3B1 inhibitor drugs on cells with or without partial loss of SF3b1 is not clear from the data shown. Knockdown efficiency of the single shRNA used in [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"} is not shown, only 2 cell lines are studied (as opposed to the larger number of lines shown in [Figure 2A](#fig2){ref-type="fig"}), and the authors have not tested the isogenic Cal51 CRISPR SF3b1 loss cell line in this experiment (only the parental Cal51 cells).

3\) In [Figure 6](#fig6){ref-type="fig"}, it is not clear why intron retention is specifically focused on given that loss of SF3B1 in SFB1 copy number deleted cells should cause failure of constitutive splicing and all classes of alternative splicing. In fact, this point is suggested by the single RT-PCR example shown (MCL1 splicing; [Figure 6D](#fig6){ref-type="fig"}) is a cassette exon-skipping event and not due to a change in intron retention or 3\' splice site selection. Evaluating the splicing in these cells in more detail from the RNA-seq data and representative RT-PCR events would be helpful.

4\) In [Figures 2](#fig2){ref-type="fig"}--[3](#fig3){ref-type="fig"} the authors suggest that cells with partial loss of SF3B1 are more susceptible to SF3B1 downregulation however qRT-PCR data for [Figure 2A](#fig2){ref-type="fig"} are either not shown in an ideal manner to make this point and no Western blot is provided for this Figure (which may be understandable given that suppression of SF3B1 is lethal). [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"} gives the suggestion that SF3B1 is similarly suppressed across these cell lines following shRNA treatment but this is not the case. It would also be helpful to show the effects of complete SF3B1 downregulation on cell growth across all cell lines as these data may give the impression that knockdown of SF3B1 is tolerated in some cell types (which is not the case).

5\) The selectivity of b-AP15 for SF3B1 versus other substrates is not clear. It is possible that this compound exhibits preferential effects on SF3B1 partial loss cells due to effects on SF3B1 ubiquitination in addition to ubiquitination of other substrates that are not known. Although the authors acknowledge this point, it will be important to at least examine the effect of b-AP15 on splicing/gene expression compared to knockdown of SF3B1 (as in point above) to determine whether there is a similar \"signature\" of altered splicing to that obtained with SF3B1 inhibition. Moreover, if it were possible to see if SF3B1 re-expression could rescue the effects of b-AP15 that would be helpful as well.

6).[Figure 3E](#fig3){ref-type="fig"} is underexposed relative to [Figure 3C](#fig3){ref-type="fig"}. SF3B1 is readily visible in BT549 cells in [Figure 3C](#fig3){ref-type="fig"} but not in [Figure 3E](#fig3){ref-type="fig"}.

7\) The cell lines analyzed in [Figure 3F](#fig3){ref-type="fig"} should be labeled in the figure.

8\) A direct comparison of SF3B1 mRNA and protein levels could be informative and help readers to understand whether reductions in mRNA levels fully explain the observed differences in protein level. The authors could illustrate this with a scatter plot or similar illustration.

9\) There are several issues with the statistical analyses that should be addressed:

The authors use Fisher\'s exact test when testing for a difference in proportion. However, the assumptions of the test are not met, because the margins are not fixed. The authors should use the binomial proportion test instead, which does not assume that the margins are fixed. (This is a common mistake and may not change any conclusions; however, it is a statistical error that should be addressed).

The \"novel statistical framework\" that was used to analyze the RNA-seq data needs further explanation. Since the method is new and relevant to interpreting the data, it should be at least partially described in the main text. The description in the supplementary should also be fleshed out. For example, the authors should describe how the \"risk of intron retention\" relates to the more standard \"psi\" value (fraction of mRNAs of the parent gene containing the retained intron) in terms comprehensible to a non-statistically minded reader. An explanation of why a β-binomial distribution is superior to the more standard binomial distribution would also be helpful (e.g., from a biological perspective, the binomial distribution assumes that the probability of intron retention is fixed, while the β-binomial distribution instead assumes that the probability varies).
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Author response

*Essential revisions:*

*1) It is unclear in [Figure 5](#fig5){ref-type="fig"} if partial copy number of loss of SF3B1 reduces levels of U2 snRNP and/or if this occurs only following further depletion of SF3B1. It is also not clear why partial reduction of SF3b1 would reduce expression of other U2 snRNP components and U2 snRNA (unless the cells experience reduce levels of these components simply due to reduced viability upon further SF3B1 suppression).*

We primarily evaluated the effect of SF3B1 copy-loss on the U2 snRNP and SF3b complex in [Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} without SF3B1 suppression. In contrast, [Figure 5](#fig5){ref-type="fig"} evaluated the effect of SF3B1 copy-loss on U2 snRNP and precursor complexes after SF3B1 suppression. Quantification of large protein complexes such as the U2 snRNP (\>800 kDa) can be technically challenging. However, [Figure 5](#fig5){ref-type="fig"} provides additional data that is consistent with the conclusions of [Figure 4](#fig4){ref-type="fig"} that SF3B1 copy-loss reduces SF3b precursor complex, but does not substantially reduce 17S U2 snRNP abundance unless SF3B1 expression is suppressed.

Given the reviewers' concerns, we now have quantified immunoblots blots from replicate glycerol gradients from [Figure 5B-C](#fig5){ref-type="fig"} in the new [Figure 5---figure supplement 1B-D](#fig5s1){ref-type="fig"}. There was a small but statistically insignificant trend towards decreased U2 snRNP levels in SF3B1^loss^ cells without SF3B1 suppression (Fraction 25), compared to substantial and significant loss of SF3B1 in smaller complexes such as SF3b (Fractions 4-6). We have revised the manuscript as follows:

Results:

"Consistent with [Figure 4](#fig4){ref-type="fig"}, *SF3B1^loss^* cells without *SF3B1* suppression did not have significantly lower levels of U2 snRNP in fraction 25 than *SF3B1^neutral^* cells (p=0.16, [Figure 5---figure supplement 1B-D](#fig5s1){ref-type="fig"}), suggesting *SF3B1* copy-loss only reduces levels of the U2 snRNP following further depletion of *SF3B1*."

We also observed that partial SF3B1 suppression reduced overall protein expression of U2 snRNP components SF3A3, SNRPB2 ([Figure 5A-C](#fig5){ref-type="fig"}), and the U2 snRNA ([Figure 5F](#fig5){ref-type="fig"}) in SF3B1^loss^ cells. The immunoblots and qPCR detecting these changes were performed four days after the addition of doxycycline, at a time point before the induction of apoptosis. Therefore, reduced levels of these components simply due to reduced viability upon further SF3B1 suppression is less likely. Another possibility is that the reduction in these non-SF3B1 U2 snRNP components is due to the relative instability of U2 snRNP precursors compared to their stability when assembled into the U2 snRNP. However, we have not formally evaluated this hypothesis.

We therefore now describe this caveat in the Discussion:

"We also observed decreased protein levels of SNRPB2, SF3A3 and the U2 snRNA in *SF3B1^loss^* cells after *SF3B1* suppression ([Figure 5A and 5F](#fig5){ref-type="fig"}). \[...\] Although these experiments were performed prior to detection of apoptosis, we cannot exclude the possibility that decreased U2 precursor complexes are a result of decreased cell viability beyond the level of detection."

*2) The lack of efficacy of SF3B1 inhibitor drugs on cells with or without partial loss of SF3b1 is not clear from the data shown. Knockdown efficiency of the single shRNA used in [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"} is not shown, only 2 cell lines are studied (as opposed to the larger number of lines shown in [Figure 2A](#fig2){ref-type="fig"}), and the authors have not tested the isogenic Cal51 CRISPR SF3b1 loss cell line in this experiment (only the parental Cal51 cells).*

We agree that additional cell lines would enhance the understanding of whether SF3B1^loss^ cells are more sensitive to chemical modulation of the spliceosome. In response, we profiled five additional cell lines with spliceosome modulators including two pairs of isogenic Cal51 CRISPR SF3B1^loss^ cell lines and HMC1-8, a SF3B1^neutral^ line with stable SF3B1 suppression. Consistent with our previous findings, we were unable to detect enhanced sensitivity of isogenic SF3B1^loss^ cells or SF3B1^neutral^ cells with partial SF3B1 suppression to spliceosome modulators and even observed a trend in the opposite direction ([Figure 5---figure supplement 1G-I](#fig5s1){ref-type="fig"}).

The lack of sensitivity of cells with reduced SF3B1 protein levels generally agrees with the current mechanism of action of spliceosome modulatory drugs. These inhibitors are thought to modulate U2 snRNP function to alter splicing resulting in cell death (Corrionero et al., 2011; Folco et al., 2011; Roybal and Jurica, 2010). With similar U2 snRNP levels in *SF3B1^loss^* and *SF3B1^neutral^* cells ([Figure 4](#fig4){ref-type="fig"}), the lack of sensitivity to spliceosome modulation is not completely unexpected.

However, we identified 19 additional candidate CYCLOPS genes that are members of the spliceosome, which suggests other CYCLOPS gene dependences may be targeted by spliceosome modulators. Furthermore, copy number alterations affecting spliceosome genes may be an important consideration when evaluating the effectiveness of spliceosome modulators.

We have therefore revised the Results section as follows:

"The relative preservation of the U2 snRNP and larger complexes in *SF3B1^loss^* cells without *SF3B1* suppression suggests existing SF3b inhibitors might not exploit the specific vulnerability exhibited by *SF3B1^loss^* cells. \[...\] We also evaluated isogenic Cal51 cells with engineered SF3B1 copy-loss and did not observe enhanced sensitivity of SF3B1^loss-Cal51^ cell lines ([Figure 5---figure supplement 1I](#fig5s1){ref-type="fig"})."

We also provide the knockdown efficiency of the shRNAs used in SF3B1^neutral^ cells with partial SF3B1 suppression in [Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"} for Cal51 and Hs578T, and [Figure 5---figure supplement 1G](#fig5s1){ref-type="fig"} for HMC 1-8.

*3) In [Figure 6](#fig6){ref-type="fig"}, it is not clear why intron retention is specifically focused on given that loss of SF3B1 in SFB1 copy number deleted cells should cause failure of constitutive splicing and all classes of alternative splicing. In fact, this point is suggested by the single RT-PCR example shown (MCL1 splicing; [Figure 6D](#fig6){ref-type="fig"}) is a cassette exon-skipping event and not due to a change in intron retention or 3\' splice site selection. Evaluating the splicing in these cells in more detail from the RNA-seq data and representative RT-PCR events would be helpful.*

We agree that disruption of SF3B1 protein function is likely to impact additional classes of splicing besides intron retention or 3' splice site selection. We have now extended our analyses to include 5' splice site selection and cassette exon-skipping. SF3B1^loss^ cells demonstrated increased dysregulation of 5' splice site selection with SF3B1 suppression, consistent with our prior results on intron retention and 3' splice site selection. A larger proportion of 5' splice sites were significantly more affected by SF3B1 suppression in SF3B1^loss^ cells (1411 junctions vs. 317, p = 9x10^-165^, [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). We also observed increased dysregulation of cassette exon inclusion ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). The proportion of reads including the cassette exon at each junction changed substantially after SF3B1 suppression in SF3B1^loss^ cells, but was less substantially altered in SF3B1^neutral^ cells.

We have also validated alternative 3' splice site junctions observed to be more frequently improperly spliced in SF3B1^loss^ cells. RT-PCR results demonstrated increased 3' splice sites in SF3B1^loss^ cells after SF3B1 suppression, consistent with the RNA-sequencing data ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}).

We have therefore revised the Results section as follows:

"The SF3b complex is known to regulate 3' splice site selection (DeBoever et al., 2015). We therefore analyzed 30,666 alternative 3' splice sites from the RNAseq data in *SF3B1^neutral^* and *SF3B1^loss^* cells. \[...\] Together, these data indicate that *SF3B1* suppression more substantially dysregulates splicing of the transcriptome of *SF3B1^loss^* cells."

*4) In [Figures 2](#fig2){ref-type="fig"}--[3](#fig3){ref-type="fig"} the authors suggest that cells with partial loss of SF3B1 are more susceptible to SF3B1 downregulation however qRT-PCR data for [Figure 2A](#fig2){ref-type="fig"} are either not shown in an ideal manner to make this point and no Western blot is provided for this Figure (which may be understandable given that suppression of SF3B1 is lethal). [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"} gives the suggestion that SF3B1 is similarly suppressed across these cell lines following shRNA treatment but this is not the case. It would also be helpful to show the effects of complete SF3B1 downregulation on cell growth across all cell lines as these data may give the impression that knockdown of SF3B1 is tolerated in some cell types (which is not the case).*

We agree and in response have provided new data and revised presentation of previous data to more clearly describe the levels of SF3B1 at baseline and upon SF3B1 suppression in SF3B1^neutral^ and SF3B1^loss^ cells. We agree with the reviewers that Western blot data demonstrating SF3B1 suppression can be challenging given that complete SF3B1 suppression is lethal. Therefore, we used qPCR more frequently to provide a reliable method to evaluate SF3B1 expression at time points 2-3 days after shRNA expression before the loss of cell viability. To highlight the important differences in baseline SF3B1 expression and the extent of suppression achieved by shSF3B1 hairpins, we calculated the relative overall expression of SF3B1, normalized to the diploid cell line Cal51. Data now represent relative SF3B1 expression before and after knockdown for 11 cell lines (7 SF3B1^neutral^ and 4 SF3B1^loss^) and now present these as a main figure panel ([Figure 2B](#fig2){ref-type="fig"}).

To address the level of SF3B1 knockdown at the protein level, we also performed SF3B1 immunoblots from a subset of cell lines studied. Two SF3B1^neutral^ and two SF3B1^loss^ cell lines were evaluated for SF3B1 protein expression by immunoblot two days after SF3B1 suppression using shSF3B1 \#3. These Western blots were performed in parallel from cells infected and assayed by growth curves in [Figure 2A](#fig2){ref-type="fig"} that are now included in [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}.

We also provide new data to show the effects of complete SF3B1 downregulation on cell growth in SF3B1^neutral^ cells to reinforce the concept that complete loss of SF3B1 expression is not tolerated by any cell regardless of SF3B1 copy number status ([Figure 2---figure supplement 1B-C](#fig2s1){ref-type="fig"}).

As a result, we have revised the Results section as follows:

"Upon partial *SF3B1* suppression, *SF3B1^loss^* cells exhibited significant growth defects but *SF3B1^neutral^* cells or *SF3B1^gain^*cells did not ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). \[...\] However, complete *SF3B1* suppression resulted in growth defects even in *SF3B1^neutral^* cells ([Figure 2---figure supplement 1B-C](#fig2s1){ref-type="fig"}), consistent with previous work establishing *SF3B1* as an essential gene."

We have also revised the text throughout to emphasize that it is partial SF3B1 suppression that is tolerated in SF3B1^neutral^ cells.

*5) The selectivity of b-AP15 for SF3B1 versus other substrates is not clear. It is possible that this compound exhibits preferential effects on SF3B1 partial loss cells due to effects on SF3B1 ubiquitination in addition to ubiquitination of other substrates that are not known. Although the authors acknowledge this point, it will be important to at least examine the effect of b-AP15 on splicing/gene expression compared to knockdown of SF3B1 (as in point above) to determine whether there is a similar \"signature\" of altered splicing to that obtained with SF3B1 inhibition. Moreover, if it were possible to see if SF3B1 re-expression could rescue the effects of b-AP15 that would be helpful as well.*

We agree that the DUBi b-AP15 is unlikely to be entirely selective for SF3B1 degradation, especially across a wide range of doses where inhibition of multiple DUBs is possible. In response, we provide new experimental evidence that suggests b-AP15 may specifically target SF3B1 to reduce SF3B1^loss^ cell viability at nanomolar concentrations that are lower than previously reported activity (D\'Arcy et al., 2015). We determined the effect of b-AP15 treatment on previously identified splicing alterations that result from SF3B1 suppression to evaluate whether a similar "signature" of splicing alterations occurred during SF3B1 suppression and b-AP15 treatment. Increased intron retention was observed in SF3B1^loss^ cells, but not SF3B1^neutral^ cells treated with 550 nM b-AP15 in all three genes tested ([Figure 8E](#fig8){ref-type="fig"}). We also used a luciferase splicing reporter assay to demonstrate that splicing can be inhibited in SF3B1^loss^ cells at 350 nM b-AP15 concentration ([Figure 8F-G](#fig8){ref-type="fig"}). Of note, b-AP15 seems to stimulate splicing in the SF3B1^neutral^ cell controls in this experiment, an incidental finding that we do not understand but could be due to any number of non-specific effects of b-AP15 on these controls cells.

Importantly we also performed "rescue" experiments to demonstrate the specificity of b-AP15. Enhanced SF3B1 expression during b-AP15 treatment allowed SF3B1^loss^ cells to tolerate higher concentrations of b-AP15, similar to that of SF3B1^neutral^ cells without SF3B1 expression ([Figure 8H](#fig8){ref-type="fig"}). However increased SF3B1 expression in SF3B1^neutral^ cells did not further increase cell viability during b-AP15 exposure. This suggests that non-SF3B1 effects are important considerations when exposing SF3B1^neutral^ cells to higher concentrations of b-AP15.

There is much yet to determine regarding b-AP15 and the SF3B1 CYCLOPS dependency, not least of which is whether we can more specifically target DUBs responsible for SF3B1 degradation. However, we feel that these b-AP15 DUBi studies represent a step change in our understanding of CYCLOPS dependencies in general in that they demonstrate that enhancing degradation of CYCLOPS genes through DUB inhibition can be a promising and generalizable approach to target CYCLOPS gene dependencies.

We describe these new data in the Results section:

"Treatment of cells with b-AP15 resulted in splicing alterations preferentially in *SF3B1^loss^* cells. \[...\] Lastly, rescue experiments in which we expressed exogenous *SF3B1* increased the concentration of b-AP15 required to impact cell viability in *SF3B1^loss^* cells, but did not affect the sensitivity of *SF3B1^control^*^-Cal51-2^ cells ([Figure 8H](#fig8){ref-type="fig"})."

*6) [Figure 3E](#fig3){ref-type="fig"} is underexposed relative to [Figure 3C](#fig3){ref-type="fig"}. SF3B1 is readily visible in BT549 cells in [Figure 3C](#fig3){ref-type="fig"} but not in [Figure 3E](#fig3){ref-type="fig"}.*

We agree and now provide a short and long exposure of the SF3B1 immunoblot. The longer exposure in revised [Figure 3F](#fig3){ref-type="fig"} more clearly shows SF3B1 in BT549 cells.

*7) The cell lines analyzed in [Figure 3F](#fig3){ref-type="fig"} should be labeled in the figure.*

We have now included the names of the cell lines analyzed in [Figure 3G](#fig3){ref-type="fig"}.

*8) A direct comparison of SF3B1 mRNA and protein levels could be informative and help readers to understand whether reductions in mRNA levels fully explain the observed differences in protein level. The authors could illustrate this with a scatter plot or similar illustration.*

We agree and provide the requested scatter plot in [Figure 3E](#fig3){ref-type="fig"}. We calculated SF3B1 protein abundance relative to the diploid cell line Cal51 after normalizing for protein loading (See Appendix Methods "Quantification of western blots by densitometry"). We observed a significant correlation between SF3B1 mRNA and protein levels (p = 0.0018, R^[@bib2]^ =0.772, regression line slope = 0.789). These data indicate that SF3B1 mRNA expression has a major influence on SF3B1 protein levels, but leave open the possibility that post-translational regulation has modest additional effects on SF3B1 protein levels.

*9) There are several issues with the statistical analyses that should be addressed:*

*The authors use Fisher\'s exact test when testing for a difference in proportion. However, the assumptions of the test are not met, because the margins are not fixed. The authors should use the binomial proportion test instead, which does not assume that the margins are fixed. (This is a common mistake and may not change any conclusions; however, it is a statistical error that should be addressed).*

We thank the reviewers for this helpful comment. We have now tested for differences in proportions using binomial proportions tests and have revised the p values as a result. As indicated by the reviewers, no conclusions were altered.

We have revised the Results section as follows:

"We also examined the reproducibility of the CYCLOPS analysis using a separate shRNA viability screen across 77 cell lines with a separate analytical approach (Marcotte et al., 2016) and found 49% (49/103) of the CYCLOPS genes analyzed by both datasets validated in the Marcotte dataset (p\<2x10^-4^, binomial proportion test)."

"Candidate CYCLOPS genes are also enriched for essential genes. Genome-wide CRISPR viability data in human cancer cell lines identified 1,580 core-essential genes (Hart et al., 2015), including 58% (72/124) of candidate CYCLOPS genes (p\<2x10^-4^, binomial proportion test)."

*The \"novel statistical framework\" that was used to analyze the RNA-seq data needs further explanation. Since the method is new and relevant to interpreting the data, it should be at least partially described in the main text. The description in the supplementary should also be fleshed out. For example, the authors should describe how the \"risk of intron retention\" relates to the more standard \"psi\" value (fraction of mRNAs of the parent gene containing the retained intron) in terms comprehensible to a non-statistically minded reader. An explanation of why a β-binomial distribution is superior to the more standard binomial distribution would also be helpful (e.g., from a biological perspective, the binomial distribution assumes that the probability of intron retention is fixed, while the β-binomial distribution instead assumes that the probability varies).*

We agree and have taken the following steps to enhance the clarity and interpretation of our RNAseq splicing analyses. We now provide a general description of the approach in the main Results section:

"Briefly, we calculated the ratio of percent spliced in (PSI) and spliced out read counts for each splicing junction, but accounted for the probability that any single splicing junction may not be accurately sampled in each cell line by using a β binomial distribution (see Appendix Methods)."

We also have revised our full description of RNAseq splicing analysis in the Appendix Methods. We have changed our original description of "risk of intron retention" in terms of the more standard percent spliced in "PSI" value and define the β binomial probabilities of splicing alterations in terms of PSI. We also provide an explanation of why a β binomial distribution can aid in the assessment of splicing alterations instead of a more standard binomial distribution given the relatively low numbers of reads that span splice junctions.

The text of the Appendix Methods has been modified as follows:

"JuncBASE was used to determine the spliced in/spliced out counts at each splice junction. \[...\] We capture the extent of this inaccuracy by calculating an estimate of the probability distribution of the true PSI, given the read counts observed. The β binomial distribution is used in cases like this where one is attempting to obtain an estimate of the distribution of a Bernoulli random variable (true PSI) from a set of observations of trials and successes."

[^1]: These authors contributed equally to this work.
